RITE AID CORP - Quarter Report: 2019 August (Form 10-Q)

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended August 31, 2019

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 1-5742

RITE AID CORPORATION

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)	23-1614034 (I.R.S. Employer Identification No.)

30 Hunter Lane, Camp Hill, Pennsylvania (Address of principal executive offices)	17011 (Zip Code)

Registrant’s telephone number, including area code: (717) 761-2633.

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report):

Not Applicable

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $1.00 par value		RAD		New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ⌧ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “Large Accelerated Filer,” “Accelerated Filer,” “Smaller Reporting Company” and “Emerging Growth Company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ⌧

Accelerated Filer ◻

Non-Accelerated Filer ◻

Smaller reporting company ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange act). Yes ☐ No ⌧

The registrant had 54,874,888 shares of its $1.00 par value common stock outstanding as of September 25, 2019.

Table of Contents

RITE AID CORPORATION

TABLE OF CONTENTS


	Cautionary Statement Regarding Forward-Looking Statements	3

	PART I FINANCIAL INFORMATION

ITEM 1.	Financial Statements (unaudited):
	Condensed Consolidated Balance Sheets as of August 31, 2019 and March 2, 2019	6
	Condensed Consolidated Statements of Operations for the Thirteen Week Periods Ended August 31, 2019 and September 1, 2018	7
	Condensed Consolidated Statements of Comprehensive Loss for the Thirteen Week Periods Ended August 31, 2019 and September 1, 2018	8
	Condensed Consolidated Statements of Operations for the Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018	9
	Condensed Consolidated Statements of Comprehensive Loss for the Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018	10
	Condensed Consolidated Statements of Stockholders’ Equity for the Thirteen and Twenty-Six Week Periods Ended August 31, 2019	11
	Condensed Consolidated Statements of Stockholders’ Equity for the Thirteen and Twenty-Six Week Periods Ended September 1, 2018	12
	Condensed Consolidated Statements of Cash Flows for the Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018	13
	Notes to Condensed Consolidated Financial Statements	14
ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations	57
ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	71
ITEM 4.	Controls and Procedures	72

	PART II OTHER INFORMATION

ITEM 1.	Legal Proceedings	73
ITEM 1A.	Risk Factors	73
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	73
ITEM 3.	Defaults Upon Senior Securities	73
ITEM 4.	Mine Safety Disclosures	73
ITEM 5.	Other Information	73
ITEM 6.	Exhibits	73

Table of Contents

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This report, as well as our other public filings or public statements, include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by terms and phrases such as “anticipate,” “believe,” “intend,” “estimate,” “expect,” “continue,” “should,” “could,” “may,” “plan,” “project,” “predict,” “will” and similar expressions and include references to assumptions and relate to our future prospects, developments and business strategies.

Factors that could cause actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:

●

our high level of indebtedness and our ability to make interest and principal payments on our debt and satisfy the other covenants contained in our credit facilities and other debt agreements;

●

the ongoing impact of private and public third party payors’ continued reduction in prescription drug reimbursement rates and their efforts to limit access to payor networks, including through mail order;

●

our ability to achieve the benefits of our efforts to reduce the costs of our generic and other drugs, and our ability to achieve and sustain drug pricing efficiencies;

●

the risk that changes in federal or state laws or regulations, including the Health Care Education Affordability Reconciliation Act, the repeal of all or part of the Patient Protection and the Affordable Care Act (or "ACA") and any regulations enacted thereunder may occur;

●

the impact of the loss of one or more major third party payor contracts;

●

the inability to complete the sale of remaining distribution centers to Walgreens Boots Alliance, Inc. (“WBA”), due to the failure to satisfy the minimal remaining conditions applicable only to the distribution centers being transferred at such distribution center closing;

●

the impact on our business, operating results and relationships with customers, suppliers, third party payors, and employees, resulting from our efforts over the past several years to consummate significant transactions with WBA and Albertsons Companies, Inc.;

●

the risk that we will not be able to meet our obligations under our Transition Services Agreement (“TSA”) with WBA, which could expose us to significant financial penalties;

●

the risk that we cannot reduce our selling, general and administrative expenses enough to offset lost income from the TSA as the amount of stores serviced under the agreement decreases;

●

the risk that we may need to take further impairment charges if our future results do not meet our expectations;

●

our ability to refinance our indebtedness on terms favorable to us;

●

our ability to improve the operating performance of our stores in accordance with our long term strategy;

●

our ability to grow prescription count and realize front-end sales growth;

●

our ability to successfully execute and achieve benefits from our recent changes in senior management and organizational restructuring;

●

our ability to hire and retain qualified personnel;

Table of Contents

●

our ability to achieve cost savings through the organizational restructurings within our anticipated timeframe, if at all;

●

decisions to close additional stores and distribution centers or undertake additional refinancing activities, which could result in further charges;

●

our ability to manage expenses and working capital;

●

continued consolidation of the drugstore and the pharmacy benefit management (“PBM”) industries;

●

the risk that provider and state contract changes may occur;

●

risks related to compromises of our information or payment systems or unauthorized access to confidential or personal information of our associates or customers;

●

our ability to maintain our current pharmacy services business and obtain new pharmacy services business, including maintaining renewals of expiring contracts, avoiding contract termination rights that may permit certain of our clients to terminate their contracts prior to their expiration, early price renegotiations prior to contract expirations and the risk that we cannot meet client guarantees;

●

the continued impact of gross margin pressure in the PBM industry due to increased market competition and client demand for lower prices while providing enhanced service offerings;

●

our ability to maintain our current Medicare Part D business and obtain new Medicare Part D business, as a result of the annual Medicare Part D competitive bidding process and meet the financial obligations of our bid;

●

the expiration or termination of our Medicare or Medicaid managed care contracts by federal or state governments;

●

risks related to other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange or interest rates or credit ratings, changes in tax laws, regulations, rates and policies or competitive development including aggressive promotional activity from our competitors;

●

the risk that we could experience deterioration in our current Star rating with the Centers of Medicare and Medicaid Services (“CMS”) or incur CMS penalties and/or sanctions;

●

the nature, cost and outcome of pending and future litigation and other legal proceedings or governmental investigations, including any proceedings related to our industry and pharmaceutical companies generally as well as those related to the sale of stores to WBA;

●

the potential reputational risk to our business during the period in which WBA is operating the Acquired Stores (as defined herein) under the Rite Aid banner;

●

the inability to fully realize the benefits of our tax attributes; and

●

other risks and uncertainties described from time to time in our filings with the Securities and Exchange Commission (the “SEC”).

We undertake no obligation to update or revise the forward-looking statements included in this report, whether as a result of new information, future events or otherwise, after the date of this report. Our actual results, performance or

Table of Contents

achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Factors that could cause or contribute to such differences are discussed in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations” included herein and in our Annual Report on Form 10-K for the fiscal year ended March 2, 2019 (the “Fiscal 2019 10-K"), which we filed with the SEC on April 25, 2019, and our Quarterly Report on Form 10-Q for the thirteen weeks ended June 1, 2019, which we filed on July 11, 2019, as well as in the "Risk Factors" section of the Fiscal 2019 10-K. These documents are available on the SEC’s website at www.sec.gov.

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements

RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)

(unaudited)


	August 31,		March 2,
	2019		2019
ASSETS
Current assets:
Cash and cash equivalents	$	142,181	$	144,353
Accounts receivable, net		1,945,600		1,788,712
Inventories, net of LIFO reserve of $619,437 and $604,444		1,968,937		1,871,941
Prepaid expenses and other current assets		183,428		179,132
Current assets held for sale		145,213		117,581
Total current assets		4,385,359		4,101,719
Property, plant and equipment, net		1,270,467		1,308,514
Operating lease right-of-use assets		2,944,651		—
Goodwill		1,108,136		1,108,136
Other intangibles, net		381,369		448,706
Deferred tax assets		382,105		409,084
Other assets		201,126		215,208
Total assets	$	10,673,213	$	7,591,367
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current maturities of long-term debt and lease financing obligations	$	10,704	$	16,111
Accounts payable		1,570,178		1,618,585
Accrued salaries, wages and other current liabilities		732,787		808,439
Current portion of operating lease liabilities		502,706		—
Current liabilities held for sale		43,364		—
Total current liabilities		2,859,739		2,443,135
Long-term debt, less current maturities		3,834,605		3,454,585
Long-term operating lease liabilities		2,745,598		—
Lease financing obligations, less current maturities		22,540		24,064
Other noncurrent liabilities		250,145		482,893
Total liabilities		9,712,627		6,404,677
Commitments and contingencies		—		—
Stockholders’ equity:
Common stock, par value $1 per share; 75,000 shares authorized; shares issued and outstanding 54,896 and 54,016		54,896		54,016
Additional paid-in capital		5,885,550		5,876,977
Accumulated deficit		(4,948,958)		(4,713,244)
Accumulated other comprehensive loss		(30,902)		(31,059)
Total stockholders’ equity		960,586		1,186,690
Total liabilities and stockholders’ equity	$	10,673,213	$	7,591,367

See accompanying notes to condensed consolidated financial statements.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(unaudited)


	Thirteen Week Period Ended
	August 31, 2019		September 1, 2018
Revenues	$	5,366,264	$	5,421,362
Costs and expenses:
Cost of revenues		4,221,825		4,260,211
Selling, general and administrative expenses		1,135,530		1,153,991
Lease termination and impairment charges		1,471		39,609
Goodwill and intangible asset impairment charges		—		375,190
Interest expense		60,102		56,233
Gain on sale of assets, net		(1,587)		(4,965)
		5,417,341		5,880,269
Loss from continuing operations before income taxes		(51,077)		(458,907)
Income tax expense (benefit)		27,628		(106,559)
Net loss from continuing operations		(78,705)		(352,348)
Net loss from discontinued operations, net of tax		(574)		(6,792)
Net loss	$	(79,279)	$	(359,140)
Computation of loss attributable to common stockholders:
Loss from continuing operations attributable to common stockholders—basic and diluted	$	(78,705)	$	(352,348)
Loss from discontinued operations attributable to common stockholders—basic and diluted		(574)		(6,792)
Loss attributable to common stockholders—basic and diluted	$	(79,279)	$	(359,140)
Basic and diluted loss per share:
Continuing operations	$	(1.48)	$	(6.67)
Discontinued operations	$	(0.01)	$	(0.13)
Net basic and diluted loss per share	$	(1.49)	$	(6.80)

See accompanying notes to condensed consolidated financial statements.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands)

(unaudited)


	Thirteen Week Period Ended
	August 31, 2019		September 1, 2018
Net loss	$	(79,279)	$	(359,140)
Other comprehensive income:
Defined benefit pension plans:
Amortization of net actuarial losses included in net periodic pension cost, net of $0 and $144 tax expense		415		364
Change in fair value of interest rate cap		(17)		—
Total other comprehensive income		398		364
Comprehensive loss	$	(78,881)	$	(358,776)

See accompanying notes to condensed consolidated financial statements.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(unaudited)


	Twenty-Six Week Period Ended
	August 31, 2019		September 1, 2018
Revenues	$	10,738,853	$	10,809,852
Costs and expenses:
Cost of revenues		8,467,691		8,479,952
Selling, general and administrative expenses		2,298,182		2,306,618
Lease termination and impairment charges		1,949		49,468
Goodwill and intangible asset impairment charges		—		375,190
Interest expense		118,372		119,025
Loss on debt retirements, net		—		554
Gain on sale of assets, net		(4,299)		(10,824)
		10,881,895		11,319,983
Loss from continuing operations before income taxes		(143,042)		(510,131)
Income tax expense (benefit)		35,002		(116,056)
Net loss from continuing operations		(178,044)		(394,075)
Net (loss) income from discontinued operations, net of tax		(894)		249,351
Net loss	$	(178,938)	$	(144,724)
Computation of loss attributable to common stockholders:
Loss from continuing operations attributable to common stockholders—basic and diluted	$	(178,044)	$	(394,075)
(Loss) income from discontinued operations attributable to common stockholders—basic and diluted		(894)		249,351
Loss attributable to common stockholders—basic and diluted	$	(178,938)	$	(144,724)
Basic and diluted loss per share:
Continuing operations	$	(3.35)	$	(7.47)
Discontinued operations	$	(0.02)	$	4.73
Net basic and diluted loss per share	$	(3.37)	$	(2.74)

See accompanying notes to condensed consolidated financial statements.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands)

(unaudited)


	Twenty-Six Week Period Ended
	August 31, 2019		September 1, 2018
Net loss	$	(178,938)	$	(144,724)
Other comprehensive income:
Defined benefit pension plans:
Amortization of net actuarial losses included in net periodic pension cost, net of $0 and $288 tax expense		830		728
Change in fair value of interest rate cap		(673)		—
Total other comprehensive income		157		728
Comprehensive loss	$	(178,781)	$	(143,996)

See accompanying notes to condensed consolidated financial statements.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except per share amounts)

(unaudited)


								Accumulated
				Additional				Other
	Common Stock			Paid-In		Accumulated		Comprehensive
	Shares	Amount		Capital		Deficit		Loss		Total
BALANCE MARCH 2, 2019	54,016	$	54,016	$	5,876,977	$	(4,713,244)	$	(31,059)	$	1,186,690
Net loss							(99,659)				(99,659)
Other comprehensive loss:
Changes in Defined Benefit Plans, net of $0 tax expense									415		415
Change in fair value of interest rate cap									(656)		(656)
Comprehensive loss											(99,900)
Adoption of ASU 2016-02							(56,776)				(56,776)
Exchange of restricted shares for taxes	(5)		(5)		(190)						(195)
Cancellation of restricted stock	(178)		(178)		178						—
Amortization of restricted stock balance					5,016						5,016
Stock-based compensation expense					382						382
BALANCE JUNE 1, 2019	53,833		53,833		5,882,363		(4,869,679)		(31,300)		1,035,217
Net loss							(79,279)				(79,279)
Other comprehensive loss:
Changes in Defined Benefit Plans, net of $0 tax expense									415		415
Change in fair value of interest rate cap									(17)		(17)
Comprehensive loss											(78,881)
Exchange of restricted shares for taxes	(134)		(134)		(656)						(790)
Issuance of restricted stock	1,257		1,257		(1,257)						—
Cancellation of restricted stock	(60)		(60)		60						—
Amortization of restricted stock balance					5,003						5,003
Stock-based compensation expense	—		—		37						37
BALANCE AUGUST 31, 2019	54,896	$	54,896	$	5,885,550	$	(4,948,958)	$	(30,902)	$	960,586

See accompanying notes to condensed consolidated financial statements.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except per share amounts)

(unaudited)


								Accumulated
				Additional				Other
	Common Stock			Paid-In		Accumulated		Comprehensive
	Shares	Amount		Capital		Deficit		Loss		Total
BALANCE MARCH 3, 2018	53,366	$	53,366	$	5,864,664	$	(4,282,471)	$	(34,549)	$	1,601,010
Net income							214,416				214,416
Other comprehensive income:
Changes in Defined Benefit Plans, net of $144 tax expense									364		364
Comprehensive income											214,780
Adoption of ASU 2014-09							(8,547)				(8,547)
Cancellation of restricted stock	(44)		(44)		44						—
Amortization of restricted stock balance					3,381						3,381
Stock-based compensation expense					778						778
Stock options exercised	38		38		871						909
BALANCE JUNE 2, 2018	53,360		53,360		5,869,738		(4,076,602)		(34,185)		1,812,311
Net loss							(359,140)				(359,140)
Other comprehensive loss:
Changes in Defined Benefit Plans, net of $144 tax expense									364		364
Comprehensive loss											(358,776)
Exchange of restricted shares for taxes	(63)		(63)		(2,181)						(2,244)
Cancellation of restricted stock	(12)		(12)		12						—
Amortization of restricted stock balance					3,860						3,860
Stock-based compensation expense					406						406
Stock options exercised	18		18		374						392
BALANCE SEPTEMBER 1, 2018	53,303	$	53,303	$	5,872,209	$	(4,435,742)	$	(33,821)	$	1,455,949

See accompanying notes to condensed consolidated financial statements.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(unaudited)


	Twenty-Six Week Period Ended
	August 31, 2019		September 1, 2018
Operating activities:
Net loss	$	(178,938)	$	(144,724)
Net (loss) income from discontinued operations, net of tax		(894)		249,351
Net loss from continuing operations	$	(178,044)	$	(394,075)
Adjustments to reconcile to net cash used in operating activities of continuing operations:
Depreciation and amortization		166,970		184,272
Lease termination and impairment charges		1,949		49,468
Goodwill and intangible asset impairment charges		—		375,190
LIFO charge		14,993		13,324
Gain on sale of assets, net		(4,299)		(10,824)
Stock-based compensation expense		10,092		10,246
Loss on debt retirements, net		—		554
Changes in deferred taxes		26,979		(124,807)
Changes in operating assets and liabilities:
Accounts receivable		(153,269)		(323,724)
Inventories		(111,990)		(31,650)
Accounts payable		(85,623)		207,943
Operating lease right-of-use assets and operating lease liabilities		34,982		—
Other assets		(44,674)		(11,232)
Other liabilities		(8,104)		(245,587)
Net cash used in operating activities of continuing operations		(330,038)		(300,902)
Investing activities:
Payments for property, plant and equipment		(84,060)		(92,565)
Intangible assets acquired		(15,708)		(20,519)
Proceeds from dispositions of assets and investments		4,423		15,729
Proceeds from sale-leaseback transactions		—		2,587
Net cash used in investing activities of continuing operations		(95,345)		(94,768)
Financing activities:
Net proceeds from revolver		375,000		1,335,000
Principal payments on long-term debt		(3,451)		(433,746)
Change in zero balance cash accounts		54,712		(17,101)
Net proceeds from issuance of common stock		—		1,302
Payments for taxes related to net share settlement of equity awards		(986)		(2,244)
Financing fees paid for early debt redemption		—		(13)
Deferred financing costs paid		(315)		—
Net cash provided by financing activities of continuing operations		424,960		883,198
Cash flows from discontinued operations:
Operating activities of discontinued operations		(2,272)		(62,003)
Investing activities of discontinued operations		523		603,402
Financing activities of discontinued operations		—		(1,343,793)
Net cash used in discontinued operations		(1,749)		(802,394)
Decrease in cash and cash equivalents		(2,172)		(314,866)
Cash and cash equivalents, beginning of period		144,353		447,334
Cash and cash equivalents, end of period	$	142,181	$	132,468

See accompanying notes to condensed consolidated financial statements.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X and therefore do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete annual financial statements. The accompanying financial information reflects all adjustments which are of a recurring nature and, in the opinion of management, are necessary for a fair presentation of the results for the interim periods. The results of operations for the thirteen and twenty-six week periods ended August 31, 2019 are not necessarily indicative of the results to be expected for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Rite Aid Corporation (“Rite Aid”) and Subsidiaries (together with Rite Aid, the “Company”) Fiscal 2019 10-K.

In addition to the significant accounting policies discussed in the Company’s Fiscal 2019 10-K, the Company has added the following significant accounting policies as a result of its adoption of ASU No. 2016-02 and 2018-11, Leases, (Topic 842) on March 3, 2019 under the alternative transition method as permissible under ASU 2018-11 (please see Note 12. Leases, for additional details).

Recently Adopted Accounting Pronouncements

In February 2016, the FASB issued ASU No. 2016-02, Leases, (Topic 842) (“ASU-2016-02” or the “Lease Standard”), which is intended to improve financial reporting around leasing transactions. The ASU affects all companies and other organizations that engage in lease transactions (both lessee and lessor). This ASU requires organizations that lease assets—referred to as “lessees”—to recognize on the balance sheet a right of use asset (“ROU asset”) and a lease liability for the obligations created by those leases. ASU No. 2016-02 is effective for fiscal years and interim periods within those years beginning January 1, 2019.

During July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements. Among other things, ASU 2018-11 provides administrative relief by allowing entities to implement the Lease Standard using an alternative transition method. Effectively, the alternative transition method permits adoption of the Lease Standard through an adjustment to its opening balance sheet for the period of adoption, with the cumulative effect accounted for as an adjustment to retained earnings, without restating prior periods.

The Company adopted the Lease Standard on March 3, 2019 under the alternative transition method as permissible under ASU 2018-11, and applied the Lease Standard to all leases through a cumulative-effect adjustment to beginning accumulated deficit. As a result, comparative financial information has not been restated and continues to be reported under the accounting standards in effect for those periods. The Company elected the package of practical expedients permitted under the transition guidance within the Lease Standard, which includes, among other things, the ability to carry forward the existing lease classification. On March 3, 2019, the Company recorded a liability for operating leases of $3,295,327, a ROU asset for such leases of $3,026,976 and recorded an after-tax transition adjustment to increase accumulated deficit by $56,776. The Lease Standard had a material impact on the unaudited condensed consolidated balance sheet, but did not have a material impact on the unaudited condensed consolidated statement of operations or the unaudited condensed consolidated statement of cash flows.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

As permitted under the practical expedient concerning assessment of lease portfolio, the Company chose not to reassess its lease portfolio, and consequently, all existing leases that were classified as operating leases in accordance with Topic 840, continue to be classified as operating leases, and all existing leases that were classified as capital leases under Topic 840 continue to be classified as finance leases.

The Company performed an evaluation of ROU asset for impairment on transition. Stores that had previously been impaired and continued to fail the recoverability test as of March 2, 2019 were evaluated. Any store ROU asset with a carrying amount in excess of fair value was written down to the fair value. Fair value of those ROU assets was determined based on a study of market rents for similar active/operating retails sites. The result of this impairment assessment was a $81,745 write-down of the ROU assets on transition to accumulated deficit. In addition, the Company recognized $24,969 of deferred gains as a reduction to accumulated deficit upon transition related to prior sale-leaseback transactions along with other minor adjustments.

As of March 2, 2019, the Company had $124,046 in closed store and lease exit liabilities under Topic 420 (“Topic 420 Liabilities”). Under transition to Topic 842, existing Topic 420 liabilities were eliminated by recording a reduction to the ROU asset balance. However, in certain cases the Company had larger existing Topic 420 liabilities than the ROU asset balances. This excess amount of $9,333 continues to be recorded as a liability and will reduce lease expense over the remaining lease term of the affected stores. In addition, upon transition, the Company reclassified deferred rent, including unamortized tenant income allowances, prepaid rent, and favorable and unfavorable lease balances resulting from prior acquisition accounting to the ROU asset.

The following is a discussion of the Company’s lease policy under the new lease accounting standard:

The Company determines if an arrangement contains a lease at the inception of a contract. Operating lease right-of-use assets represent the Company’s right to use an underlying asset for the lease term and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and operating lease liabilities are recognized at the commencement date based on the present value of the remaining future minimum lease payments. As the interest rate implicit in the Company’s leases is not readily determinable, the Company utilizes its incremental borrowing rate, determined by class of underlying asset, to discount the lease payments. The incremental borrowing rate is determined using a portfolio approach based on the rate of interest that we would pay to borrow an amount equal to the lease payments on a collateralized basis over a similar term. We use quoted interest rates obtained from financial institutions in an input to derive our incremental borrowing rate as the discount rate for the lease. The ROU asset is equal to the operating lease liability plus lease payments made before commencement, less lease incentives received from the landlord.

The Company’s real estate leases typically contain options that permit lease extensions for additional periods of up to five years each. For real estate leases, generally, the renewal periods are not included within the lease term and the associated payments are not included in the measurement of the ROU asset and operating lease liability as the options to extend are not considered reasonably certain to occur at lease commencement. The Company reevaluates each lease on a regular basis to consider the economic and strategic incentives of exercising the renewal options and will include all reasonably certain options in the measurement of our lease term. Generally, the renewal option periods are not included within the lease term and the associated payments are not included in the measurement of the operating lease right-of-use asset and the operating lease liability until the renewals are i) evaluated and ii) determined to be exercised. The Company has an insignificant amount of non-real estate leases however, renewal options are not included in the lease term for non-

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

real estate leases because they are not considered reasonably certain of being exercised at lease commencement. The Company rarely executes leases less than 12 months. On transition, the Company did include in its ROU asset balance leases with less than 12 months remaining.

For real estate leases, the Company accounts for lease components and non-lease components as a single lease component. Certain real estate leases require additional payments based on sales volume, as well as reimbursement for real estate taxes, common area maintenance and insurance, which are expensed as incurred as variable lease costs. Other real estate leases contain one fixed lease payment that includes real estate taxes, common area maintenance and insurance. These fixed payments are considered part of the lease payment and included in the operating lease right-of-use assets and operating lease liabilities.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

Impact of the Lease Standard on Financial Statement Line Items

As a result of applying the alternative transition method to adopt the Lease Standard, the following adjustments were made to accounts on the unaudited condensed consolidated balance sheet as of March 3, 2019:


	Impact of change in accounting policy
(in thousands)	As reported				As adjusted
	March 2, 2019		Adjustments		March 3, 2019
ASSETS
Current assets:
Cash and cash equivalents	$	144,353	$	—	$	144,353
Accounts receivable, net		1,788,712		—		1,788,712
Inventories, net		1,871,941		—		1,871,941
Prepaid expenses and other current assets		179,132		(51,448)		127,684
Current assets held for sale		117,581		43,697		161,278
Total current assets		4,101,719		(7,751)		4,093,968
Property, plant and equipment, net		1,308,514		—		1,308,514
Operating lease right-of-use asset		—		3,026,976		3,026,976
Goodwill		1,108,136		—		1,108,136
Other intangibles, net		448,706		(29,632)		419,074
Deferred tax assets		409,084		—		409,084
Other assets		215,208		(1,086)		214,122
Total assets	$	7,591,367	$	2,988,507	$	10,579,874

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current maturities of long-term debt and lease financing obligations	$	16,111	$	—	$	16,111
Accounts payable		1,618,585		—		1,618,585
Accrued salaries, wages and other current liabilities		808,439		(56,553)		751,886
Current portion of operating lease liabilities		—		457,305		457,305
Current liabilities held for sale		—		45,167		45,167
Total current liabilities		2,443,135		445,919		2,889,054
Long-term debt, less current maturities		3,454,585		—		3,454,585
Long-term operating lease liabilities		—		2,838,022		2,838,022
Lease financing obligations, less current maturities		24,064		—		24,064
Other noncurrent liabilities		482,893		(238,658)		244,235
Total liabilities		6,404,677		3,045,283		9,449,960
Commitments and contingencies		—		—		—
Stockholders’ equity:
Common stock, par value $1 per share; 75,000 shares authorized; shares issued and outstanding 54,016		54,016		—		54,016
Additional paid-in capital		5,876,977		—		5,876,977
Accumulated deficit		(4,713,244)		(56,776)		(4,770,020)
Accumulated other comprehensive loss		(31,059)		—		(31,059)
Total stockholders’ equity		1,186,690		(56,776)		1,129,914
Total liabilities and stockholders’ equity	$	7,591,367	$	2,988,507	$	10,579,874

See Note 12 for additional information.

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606). ASU No. 2014-09 outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

supersedes most current revenue recognition guidance, including industry-specific guidance. In March 2016, the FASB issued ASU No. 2016-08, Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net), which amends the principal-versus-agent implementation guidance and in April 2016, the FASB issued ASU No. 2016-10, Identifying Performance Obligations and Licensing, which amends the guidance in those areas in the new revenue recognition standard. These ASUs, collectively the “new revenue standard“, are effective for annual reporting periods (including interim reporting periods within those periods) beginning January 1, 2018.

The Company adopted the new revenue standard as of March 4, 2018 using the modified retrospective method and applying the new standard to all contracts with customers. In connection with the adoption of the new revenue standard, the Company identified one difference in its Retail Pharmacy segment related to the timing of revenue recognition for third party prescription revenues, which was historically recognized at the time the prescription was filled. Upon adoption of ASU No. 2014-09, this revenue is recognized at the time the customer takes possession of the merchandise. In connection with its March 4, 2018 adoption of the new revenue standard on a modified retrospective basis, the Company recorded a reduction to accounts receivable of $57,897, a reduction to deferred tax assets of $1,771, an increase to inventory of $51,121, and a corresponding increase to accumulated deficit of $8,547 within its Retail Pharmacy segment.

In addition, the Company identified revenues under one specific rebate administration program under which the Company's Pharmacy Services segment was determined to be the principal and historically recognized revenues and cost of revenues on a gross basis of approximately $123,500 during fiscal 2018. Upon adoption of the new revenue standard, the Company is now recording revenue from this program on a net basis.

The following is a discussion of the Company's revenue recognition policies by segment under the new revenue recognition accounting standard:

Revenue Recognition

Retail Pharmacy Segment

For front-end sales, the Retail Pharmacy segment recognizes revenues upon the transfer of control of the goods to the customer. The Company satisfies its performance obligation at the point of sale for front-end transactions. The Retail Pharmacy segment front-end revenue is measured based on the amount of fixed consideration that it expects to receive, net of an allowance for estimated future returns. Return activity is immaterial to revenues and results of operations in all periods presented.

For pharmacy sales, the Retail Pharmacy segment recognizes revenue upon the transfer of control of the goods to the customer. The Company satisfies its performance obligation, upon pickup by the customer, which is when the customer takes title to the product. Each prescription claim represents an individual arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims. The Company’s revenue is measured based on the amount of fixed consideration that we expect to receive, reduced by refunds owed to the third party payor for pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not highly subjective or volatile. The effect of adjustments between estimated and actual amounts have not been material to the Company’s results of operations or financial position. Prescriptions are generally not returnable.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

The Retail Pharmacy segment offers a chain-wide loyalty card program titled wellness +. Individual customers are able to become members of the wellness + program. Members participating in the wellness + loyalty card program earn points on a calendar year basis for eligible front-end merchandise purchases and qualifying prescription purchases. One point is awarded for each dollar spent towards front-end merchandise and 25 points are awarded for each qualifying prescription.

Members reach specific wellness + tiers based on the points accumulated during the calendar year, which entitles such customers to certain future discounts and other benefits upon reaching that tier. For example, any customer that reaches 1,000 points in a calendar year achieves the "Gold" tier, enabling him or her to receive a 20% discount on qualifying purchases of front-end merchandise for the remaining portion of the calendar year and also the next calendar year. There is also a similar "Silver" level with a lower threshold and benefit level.

Points earned pursuant to the wellness+ program represent a performance obligation and the Company allocates revenue between the merchandise purchased and the wellness + points based on the relative stand-alone selling price of each performance obligation. The relative value of the wellness + points is initially deferred as a contract liability (included in other current and noncurrent liabilities). As members receive discounted front-end merchandise or when the benefit period expires, the Retail Pharmacy segment recognizes an allocable portion of the deferred contract liability into revenue. The Retail Pharmacy segment had accrued contract liabilities of $76,445 as of August 31, 2019, of which $57,901 is included in other current liabilities and $18,544 is included in noncurrent liabilities. The Retail Pharmacy segment had accrued contract liabilities of $63,720 as of March 2, 2019, of which $51,042 is included in other current liabilities and $12,678 is included in noncurrent liabilities.

The wellness + program also allows a customer to earn Bonus Cash based on qualifying purchases. Wellness + Rewards members have the opportunity to redeem their accumulated Bonus Cash on a future purchase with a 30 day expiration window.

For a majority of the Bonus Cash issuances, funding is provided by our vendors through contractual arrangements. This funding is treated as a contract liability and remains a contract liability until (i) wellness + Rewards members redeem their Bonus Cash, or (ii) wellness + Rewards members allow the Bonus Cash to expire. Upon utilization or expiration of the benefit period, the Retail Pharmacy segment recognizes an allocable portion of the accrued contract liability into revenue. For Bonus Cash issuances that are not vendor funded, the contract liability is recorded at the time of issuance through a reduction to revenues, and not recognized until the Bonus Cash is redeemed or expires.

Pharmacy Services Segment

The Pharmacy Services segment sells prescription drugs indirectly through its retail pharmacy network and directly through its mail service dispensing pharmacy. The Pharmacy Services segment recognizes revenue from prescription drugs sold by (i) its mail service dispensing pharmacy and (ii) under retail pharmacy network contracts where it is the principal at the contract prices negotiated with its clients, primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans, Medicare plans, and other sponsors of health benefit plans, and individuals throughout the United States. Revenues include: (i) the portion of the price the client pays directly to the Pharmacy Services segment, net of any volume-related or other discounts paid back to the client (see “Drug Discounts” below), (ii) the price paid to the Pharmacy Services segment by client plan members for mail order

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

prescriptions (“Mail Co-Payments”), (iii) client plan member copayments made directly to the retail pharmacy network and (iv) administrative fees. Revenue is recognized when the Pharmacy Services segment meets its performance obligations relative to each transaction type. The following revenue recognition policies have been established for the Pharmacy Services segment:

●

Revenues generated from prescription drugs sold by third party pharmacies in the Pharmacy Services segment’s retail pharmacy network and associated administrative fees are recognized at the Pharmacy Services segment’s point-of-sale, which is when the claim is adjudicated by the Pharmacy Services segment’s online claims processing system. At this point the Company has performed all of its performance obligations.

●

Revenues generated from prescription drugs sold by the Pharmacy Services segment’s mail service dispensing pharmacy are recognized when the prescription is shipped. At the time of shipment, the Pharmacy Services segment has performed all of its performance obligations under its client contracts, as control of and title to the product has passed to the client plan members. The Pharmacy Services segment does not experience a significant level of returns or reshipments.

●

Revenues generated from administrative fees based on membership or claims volume are recognized monthly based on the terms within the individual contracts, either a monthly member based fee, or a claims volume based fee.

In the majority of its contracts, the Pharmacy Services segment is the principal because its client contracts give clients the right to obtain access to its pharmacy contracts under which the Pharmacy Services segment directs its pharmacy network to provide the services (drug dispensing, consultation, etc.) and goods (prescription drugs) to the clients’ members at its negotiated pricing. The Pharmacy Services segment’s obligations under its client contracts are separate and distinct from its obligations to the third party pharmacies included in its retail pharmacy network contracts. In the majority of these contracts, the Pharmacy Services segment is contractually required to pay the third party pharmacies in its retail pharmacy network for products sold after payment is received from its clients. The Pharmacy Services segment has control over these transactions until the prescription is transferred to the member and, thus, that it is acting as a principal. As such, the Pharmacy Services segment records the total prescription price contracted with clients in revenues.

Amounts paid to pharmacies and amounts charged to clients are exclusive of the applicable co-payment under Pharmacy Services segment contracts. Retail pharmacy co-payments, which we instruct retail pharmacies to collect from members, are included in our revenues and our cost of revenues.

For contracts under which the Pharmacy Services segment acts as an agent or does not control the prescription drugs prior to transfer to the client, no revenue is recognized, except the administrative fee.

Drug Discounts—The Pharmacy Services segment deducts from its revenues that are generated from prescription drugs sold by third party pharmacies any rebates, inclusive of discounts and fees, earned by its clients based on utilization levels and other factors as negotiated with the prescription drug manufacturers or suppliers. Rebates are paid to clients in accordance with the terms of client contracts.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

Medicare Part D—The Pharmacy Services segment, through its Envision Insurance Company ("EIC") subsidiary, participates in the federal government’s Medicare Part D program as a Prescription Drug Plan (“PDP”). Please refer to Note 8, Medicare Part D.

Disaggregation of Revenue

The following tables disaggregate the Company’s revenue by major source in each segment for the thirteen and twenty-six week periods ended August 31, 2019:


	Thirteen Week Period Ended		Twenty-Six Week Period Ended
In thousands	August 31, 2019		August 31, 2019
Retail Pharmacy segment:
Pharmacy sales	$	2,561,468	$	5,137,222
Front-end sales		1,251,489		2,516,850
Other revenue		35,147		58,840
Total Retail Pharmacy segment		3,848,104		7,712,912
Pharmacy Services segment		1,579,069		3,145,361
Intersegment elimination		(60,909)		(119,420)
Total revenue	$	5,366,264	$	10,738,853

Reclassification of the Statements of Cash Flows presentation

During fiscal 2019, the Company expanded its disclosure on its Statements of Cash Flows to include changes in other assets separate from changes in other liabilities, which had historically been combined. Prior period amounts have been reclassified to conform to the current period presentation.

Recasting of per-share amounts

The Company implemented a reverse stock split of the Company’s common stock at a reverse stock split ratio of 1-for-20. The Company’s common stock began trading on a split-adjusted basis on the NYSE at the market open on April 22, 2019. Accordingly, all share and per-share amounts for the prior period has been recasted to reflect the reverse stock split.

2. Restructuring

In March 2019, the Board of Directors implemented a reorganization of our executive management team to further streamline our business. In addition, the Company announced a restructuring plan that will reduce managerial layers and consolidate roles across the organization, resulting in the elimination of approximately 400 full-time positions located at the Company’s headquarters and across the field organization. Approximately two-thirds of the reductions took place at the time of the announcement and the balance will occur by the end of fiscal 2020.

In April 2019, the Company implemented its Path to the Future transformation initiative, which focuses primarily on opportunities to drive further growth and operating efficiency, including i) building tools to work with regional health plans to improve patient health outcomes, ii) rationalize SKU’s in its front-end offering to free up

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

working capital, improve front-end profitability and improve the customer experience, iii) an assessment of the Company’s pricing and promotional strategy and, iv) a continued review of the Company’s cost structure, which includes opportunities to use technology and vendor partners to help reduce costs.

For the thirteen week period ended August 31, 2019, the Company incurred total restructuring-related costs of $25,145, which are included as a component of SG&A. These costs are as follows:


	Retail Pharmacy		Pharmacy
	segment		Services segment		Total

Restructuring-related costs
Severance and related costs associated with the March 2019 reorganization (a)	$	7,870	$	511	$	8,381
Non-executive retention costs associated with the March 2019 reorganization (b)		2,830		1,257		4,087
Professional and other fees relating to the Path to the Future transformation initiative (c)		10,355		2,322		12,677
Total restructuring-related costs	$	21,055	$	4,090	$	25,145

For the twenty-six week period ended August 31, 2019, the Company incurred total restructuring-related costs of $68,495, which are included as a component of SG&A. These costs are as follows:


	Retail Pharmacy		Pharmacy
	segment		Services segment		Total

Restructuring-related costs
Severance and related costs associated with the March 2019 reorganization (a)	$	33,142	$	2,315	$	35,457
Non-executive retention costs associated with the March 2019 reorganization (b)		7,329		3,422		10,751
Professional and other fees relating to the Path to the Future transformation initiative (c)		19,965		2,322		22,287
Total restructuring-related costs	$	60,436	$	8,059	$	68,495

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

A summary of activity for the twenty-six week period ended August 31, 2019 in the restructuring-related liabilities associated with the programs noted above, which is included in accrued salaries, wages and other current liabilities, is as follows:


	Severance and related				Professional and
	costs (a)		Retention costs (b)		other fees (c)		Total

Balance at March 2, 2019	$	—	$	4,704	$	—	$	4,704
Additions charged to expense		27,076		6,664		9,610		43,350
Cash payments		(4,653)		(242)		(9,610)		(14,505)
Balance at June 1, 2019		22,423		11,126		—		33,549
Additions charged to expense		8,381		4,087		12,677		25,145
Cash payments		(4,580)		(11,200)		(6,768)		(22,548)
Balance at August 31, 2019	$	26,224	$	4,013	$	5,909	$	36,146

(a)	– Severance and related costs reflect severance accruals, executive search fees, outplacement services and other similar charges associated with the March 2019 reorganization.

(b)	– As part of its March 2019 reorganization, the Company incurred costs with the implementation of a retention plan for certain of its key associates.

(c)	– Professional and other fees include costs incurred in connection with the identification and implementation of transformation initiatives associated with the Path to the Future initiative.

The Company anticipates its total fiscal 2020 restructuring-related costs to be approximately $90,000.

3. Asset Sale to WBA

On September 18, 2017, the Company entered into the Amended and Restated Asset Purchase Agreement with WBA and Walgreen Co., an Illinois corporation and 100% owned subsidiary of WBA (“Buyer”), which amended and restated in its entirety the previously disclosed Asset Purchase Agreement, dated as of June 28, 2017, by and among the Company, WBA and Buyer (the “Original Asset Purchase Agreement”). Pursuant to the terms and subject to the conditions set forth in the Amended and Restated Asset Purchase Agreement, Buyer agreed to purchase from the Company 1,932 stores (the “Acquired Stores”), three distribution centers, related inventory and other specified assets and liabilities related thereto for a purchase price of $4,375,000, on a cash-free, debt-free basis (the “Asset Sale” or “Sale”).

The Company announced on September 19, 2017 that the waiting period under the HSR Act, expired with respect to the Sale. The Company completed the store transfer process in March of 2018, which resulted in the transfer of all 1,932 stores and related assets to WBA, and received cash proceeds of $4,156,686.

On September 13, 2018, the Company completed the sale of one of its distribution centers and related assets to WBA for proceeds of $61,251. The impact of the sale of the distribution center and related assets resulted in a pre-tax gain of $14,151, which has been included in the results of operations and cash flows of discontinued operations during the fifty-two week period ended March 2, 2019. The transfer of the remaining two distribution centers and related assets

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

remains subject to minimal customary closing conditions applicable only to the distribution centers being transferred at such distribution center closings, as specified in the Amended and Restated Asset Purchase Agreement.

The parties to the Amended and Restated Asset Purchase Agreement have each made customary representations and warranties. The Company has agreed to various covenants and agreements, including, among others, the Company’s agreement to conduct its business at the distribution centers being sold to WBA in the ordinary course during the period between the execution of the Amended and Restated Asset Purchase Agreement and the distribution center closing. The Company has also agreed to provide transition services to Buyer for up to three years after the initial closing of the Sale. Under the terms of the TSA, the Company provides various services on behalf of WBA, including but not limited to the purchase and distribution of inventory and virtually all selling, general and administrative activities. The term of the TSA has been extended to October 17, 2020. In connection with these services, the Company purchases the related inventory and incurs cash payments for the selling, general and administrative activities, which, the Company bills on a cash neutral basis to WBA in accordance with terms as outlined in the TSA. Total billings for these items during the thirteen and twenty-six week periods ended August 31, 2019 were $913,965 and $2,106,756, respectively, of which $196,002 is included in Accounts receivable, net. Total billings for these items during the thirteen and twenty-six week periods ended September 1, 2018 were $1,835,484 and $3,876,559, respectively, of which $385,936 is included in Accounts receivable, net. The Company recorded WBA TSA fees of $11,308 and $25,533 during the thirteen and twenty-six week periods ended August 31, 2019, respectively, which are reflected as a reduction to selling, general and administrative expenses. The Company recorded WBA TSA fees of $23,213 and $46,948 during the thirteen and twenty-six week periods ended September 1, 2018, respectively, which are reflected as a reduction to selling, general and administrative expenses.

Based on its magnitude and because the Company exited certain markets, the Sale represented a significant strategic shift that has a material effect on the Company's operations and financial results. Accordingly, the Company has applied discontinued operations treatment for the Sale as required by Accounting Standards Codification 210-05-Discontinued Operations (ASC 205-20). In accordance with ASC 205-20, the Company reclassified the Disposal Group to assets and liabilities held for sale on its consolidated balance sheets as of the periods ended August 31, 2019 and March 2, 2019, and reclassified the financial results of the Disposal Group in its consolidated statements of operations and consolidated statements of cash flows for all periods presented. The Company also revised its discussion and presentation of operating and financial results to be reflective of its continuing operations as required by ASC 205-20.

The carrying amount of the Assets to be Sold, which were included in the Retail Pharmacy segment, have been reclassified from their historical balance sheet presentation to current assets and liabilities held for sale as follows:


	August 31,		March 2,
	2019		2019
Inventories	$	54,761	$	68,233
Property and equipment		49,346		49,348
Operating lease right-of-use asset		41,106		—
Current assets held for sale	$	145,213	$	117,581
Current portion of operating lease liabilities	$	3,798	$	—
Long-term operating lease liabilities		39,566		—
Current liabilities held for sale	$	43,364	$	—

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

The operating results of the discontinued operations that are reflected on the consolidated statements of operations within net income (loss) from discontinued operations are as follows:


	August 31,		September 1,		August 31,		September 1,
	2019		2018		2019		2018
	(13 weeks)		(13 weeks)		(26 weeks)		(26 weeks)
Revenues	$	(36)	$	4,716	$	(124)	$	28,116
Costs and expenses:
Cost of revenues(a)		197		182		461		17,263
Selling, general and administrative expenses(a)		379		2,570		866		16,445
Loss on debt retirements, net		—		18,075		—		22,645
Interest expense(b)		—		—		—		4,615
Loss (gain) on stores sold to Walgreens Boots Alliance		—		15		—		(360,542)
Loss (gain) on sale of assets, net		—		11		(522)		11
		576		20,853		805		(299,563)
(Loss) income from discontinued operations before income taxes		(612)		(16,137)		(929)		327,679
Income tax (benefit) expense		(38)		(9,345)		(35)		78,328
Net (loss) income from discontinued operations, net of tax	$	(574)	$	(6,792)	$	(894)	$	249,351

(a)	Cost of revenues and selling, general and administrative expenses for the discontinued operations excludes corporate overhead. These charges are reflected in continuing operations.

(b)

In accordance with ASC 205-20, the operating results for the thirteen and twenty-six week periods ended August 31, 2019 and September 1, 2018, respectively, for the discontinued operations include interest expense relating to the outstanding indebtedness repaid with the estimated excess proceeds from the Sale.

The operating results reflected above do not fully represent the Disposal Group’s historical operating results, as the results reported within net income from discontinued operations only include expenses that are directly attributable to the Disposal Group.

4. Loss Per Share

Basic loss per share is computed by dividing income available to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

resulted in the issuance of common stock that then shared in the income of the Company, subject to anti-dilution limitations.


	Thirteen Week Period Ended				Twenty-Six Week Period Ended
	August 31,		September 1,		August 31,		September 1,
	2019		2018		2019		2018
Basic and diluted loss per share:
Numerator:
Net loss from continuing operations	$	(78,705)	$	(352,348)	$	(178,044)	$	(394,075)
Net (loss) income from discontinued operations		(574)		(6,792)		(894)		249,351
Loss attributable to common stockholders— basic and diluted	$	(79,279)	$	(359,140)	$	(178,938)	$	(144,724)
Denominator:
Basic weighted average shares		53,041		52,823		53,084		52,771
Outstanding options and restricted shares, net		—		—		—		—
Diluted weighted average shares		53,041		52,823		53,084		52,771
Basic and diluted loss per share:
Continuing operations	$	(1.48)	$	(6.67)	$	(3.35)	$	(7.47)
Discontinued operations		(0.01)		(0.13)		(0.02)		4.73
Net basic and diluted loss per share	$	(1.49)	$	(6.80)	$	(3.37)	$	(2.74)

Due to their antidilutive effect, 1,367 and 1,258 potential common shares related to stock options have been excluded from the computation of diluted income (loss) per share for the thirteen and twenty-six week periods ended August 31, 2019 and September 1, 2018, respectively. Also, excluded from the computation of diluted income (loss) per share for the thirteen and twenty-six week periods ended August 31, 2019 and September 1, 2018 are restricted shares of 1,628 and 390, respectively, which are included in shares outstanding.

On April 10, 2019, the Company’s Board of Directors approved a one-for-twenty reverse stock split of the Company’s outstanding shares of common stock. The reverse stock split was effected on April 18, 2019 at 5:00 p.m. Eastern time. At the effective time, every twenty issued and outstanding shares of the Company’s common stock were converted into one share of common stock. No fractional shares were issued in connection with the reverse stock split, and in lieu thereof, each stockholder holding fractional shares was entitled to receive a cash payment (without interest or deduction) from the Company’s transfer agent in an amount equal to such stockholder’s respective pro rata shares of the total net proceeds from the Company’s transfer agent sale of all fractional shares at the then-prevailing prices on the open market. In connection with the reverse stock split, the number of authorized shares of our common stock was also reduced on a one-for-twenty basis, from 1,500,000 to 75,000. The par value of each share of common stock remained unchanged. A proportionate adjustment was also made to the maximum number of shares issuable under the Company’s 2014 Equity Incentive Plan.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

5. Lease Termination and Impairment Charges

Lease termination and impairment charges consist of amounts as follows:


	Thirteen Week Period				Twenty-Six Week Period
	Ended				Ended
	August 31,			September 1,	August 31,			September 1,
	2019		2018		2019		2018
Impairment charges	$	1,289	$	33,562	$	1,412	$	33,845
Lease termination charges		—		6,047		—		15,623
Facility exit charges		182		—		537		—
	$	1,471	$	39,609	$	1,949	$	49,468

Impairment Charges

These amounts include the write-down of long-lived assets at locations that were assessed for impairment because of management’s intention to relocate or close the location or because of changes in circumstances that indicated the carrying value of an asset may not be recoverable.

The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following:

●

Level 1—Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

●

Level 2—Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument.

●

Level 3—Inputs to the valuation methodology are unobservable inputs based upon management’s best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk.

Non-Financial Assets Measured on a Non-Recurring Basis

Long-lived non-financial assets are measured at fair value on a nonrecurring basis for purposes of calculating impairment using Level 2 and Level 3 inputs as defined in the fair value hierarchy. The fair value of long-lived assets using Level 2 inputs is determined by evaluating the current economic conditions in the geographic area for similar use assets. The fair value of long-lived assets using Level 3 inputs is determined by estimating the amount and timing of net future cash flows (which are unobservable inputs) and discounting them using a risk-adjusted rate of interest (which is Level 1). The Company estimates future cash flows based on its experience and knowledge of the market in which the store is located. Significant increases or decreases in actual cash flows may result in valuation changes. During the twenty-six week period ended August 31, 2019, long-lived assets from continuing operations with a carrying value of $1,412, primarily store assets, were written down to their fair value of $0, resulting in an impairment charge of $1,412 of

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

which $1,289 relates to the thirteen week period ended August 31, 2019. During the twenty-six week period ended September 1, 2018, long-lived assets from continuing operations with a carrying value of $40,488, primarily store assets, were written down to their fair value of $6,643, resulting in an impairment charge of $33,845 of which $33,562 relates to the thirteen week period ended September 1, 2018. If our actual future cash flows differ from our projections materially, certain stores that are either not impaired or partially impaired in the current period may be further impaired in future periods.

The following table presents fair values for those assets measured at fair value on a non-recurring basis at August 31, 2019 and September 1, 2018:


							Fair Values		Total
							as of		Charges
	Level 1		Level 2		Level 3		Impairment Date		August 31, 2019
Long-lived assets held for use	$	—	$	—	$	—	$	—	$	(1,412)
Long-lived assets held for sale	$	—	$	—	$	—	$	—	$	—
Total	$	—	$	—	$	—	$	—	$	(1,412)


							Fair Values		Total
							as of		Charges
	Level 1		Level 2		Level 3		Impairment Date		September 1, 2018
Long-lived assets held for use	$	—	$	—	$	6,643	$	6,643	$	(33,562)
Long-lived assets held for sale	$	—	$	1,292	$	—	$	1,292	$	(283)
Total	$	—	$	1,292	$	6,643	$	7,935	$	(33,845)

The above assets reflected in the caption Long-lived assets held for sale are separate and apart from the Assets to be Sold and due to their immateriality have not been reclassified to assets held for sale.

Lease Termination and Facility Exit Charges

As part of the Company's ongoing business activities, the Company assesses stores and distribution centers for potential closure or relocation. Decisions to close or relocate stores or distribution centers in future periods would result in lease termination charges, lease exit costs and inventory liquidation charges, as well as impairment of assets at these locations. When a store or distribution center is closed, the Company records an expense for unrecoverable costs and accrues a liability equal to the present value at current credit adjusted risk-free interest rates of any anticipated executory costs which are not included within the store or distribution center's respective lease liability under Topic 842. Other store or distribution center closing and liquidation costs are expensed when incurred.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

The following table reflects the closed store and distribution center charges that relate to new closures, changes in assumptions and interest accretion:


	Thirteen Week Period				Twenty-Six Week Period
	Ended				Ended
	August 31,		September 1,		August 31,		September 1,
	2019		2018		2019		2018
Balance—beginning of period	$	9,333	$	131,182	$	124,046	$	133,290
Existing Topic 420 liabilities eliminated by recording a reduction to the ROU asset		—		—		(112,288)		—
Provision for present value of noncancellable lease payments of closed stores		—		3,201		—		11,331
Changes in assumptions about future sublease income, terminations and changes in interest rates		—		324		—		(714)
Interest accretion		—		2,556		—		5,241
Cash payments, net of sublease income		(2,992)		(15,075)		(5,417)		(26,960)
Balance—end of period	$	6,341	$	122,188	$	6,341	$	122,188

6. Fair Value Measurements

The Company utilizes the three-level valuation hierarchy as described in Note 5, Lease Termination and Impairment Charges, for the recognition and disclosure of fair value measurements.

As of August 31, 2019 and March 2, 2019, the Company did not have any financial assets measured on a recurring basis.

Other Financial Instruments

Financial instruments other than long-term indebtedness include cash and cash equivalents, accounts receivable and accounts payable. These instruments are recorded at book value, which we believe approximate their fair values due to their short term nature. In addition, as of August 31, 2019 and March 2, 2019, the Company has $6,944 and $7,191, respectively, of investments carried at amortized cost as these investments are being held to maturity, which are included as a component of prepaid expenses and other current assets. The Company believes the carrying value of these investments approximates their fair value.

The fair value for LIBOR-based borrowings under the Company’s senior secured credit facility is estimated based on the quoted market price of the financial instrument which is considered Level 1 of the fair value hierarchy. The fair values of substantially all of the Company’s other long-term indebtedness are estimated based on quoted market prices of the financial instruments which are considered Level 1 of the fair value hierarchy. The carrying amount and estimated fair value of the Company’s total long-term indebtedness was $3,834,605 and $3,326,965, respectively, as of

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

August 31, 2019. The carrying amount and estimated fair value of the Company's total long-term indebtedness was $3,454,585 and $3,120,335, respectively, as of March 2, 2019.

On March 15, 2019, the Company entered into an interest rate cap (“Cap”), which has been designated to the variable interest rate payments on the first $650.0 million notional amount of variable rate indebtedness. The Cap has an effective date of March 21, 2019 and expires on March 21, 2021. The Cap provides the Company with interest rate protection in the event that LIBOR increases above 2.75%. The nominal fair market value of the Cap is recorded as a component of other assets.

7. Income Taxes

The Company recorded an income tax expense from continuing operations of $27,628 and an income tax benefit from continuing operations of $106,559 for the thirteen week periods ended August 31, 2019 and September 1, 2018 respectively, and an income tax expense from continuing operations of $35,002 and an income tax benefit from continuing operations of $116,056 for the twenty-six week periods ended August 31, 2019 and September 1, 2018, respectively. The effective tax rate for the thirteen week periods ended August 31, 2019 and September 1, 2018 was (54.1)% and 23.2%, respectively. The effective tax rate for the twenty-six week periods ended August 31, 2019 and September 1, 2018 was (24.5)% and 22.8%, respectively. The effective tax rate for the thirteen and twenty-six week periods ended August 31, 2019 was net of an adjustment of (78.4)% and (50.2)%, respectively, to increase the valuation allowance against deferred tax assets created this period as well as for certain existing state deferred taxes whose realization is now uncertain due to a restructuring of our legal entities. The effective tax rate for the thirteen and twenty-six week periods ended September 1, 2018 included an adjustment of (4.2)% and (3.9)% to increase the valuation allowance related to certain state deferred taxes.

The Company recognizes tax liabilities in accordance with the guidance for uncertain tax positions and management adjusts these liabilities with changes in judgment as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the tax liabilities.

The Company believes that it is reasonably possible that a decrease of up to $7,372 in unrecognized tax benefits related to state exposures may be necessary in the next twelve months however management does not expect the change to have a significant impact on the results of operations or the financial position of the Company.

The Company regularly evaluates valuation allowances established for deferred tax assets for which future realization is uncertain. Management will continue to monitor all available evidence related to the net deferred tax assets that may change the most recent assessment, including events that have occurred or are anticipated to occur. The Company continues to maintain a valuation allowance against net deferred tax assets of $1,088,033 and $1,091,416, which relates to federal and state deferred tax assets that may not be realized based on the Company's future projections of taxable income at August 31, 2019 and March 2, 2019, respectively.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

8. Medicare Part D

The Company offers Medicare Part D benefits through EIC, which has contracted with CMS to be a PDP and, pursuant to the Medicare Prescription Drug, Improvement and Modernization Act of 2003, must be a risk-bearing entity regulated under state insurance laws or similar statutes.

EIC is a licensed domestic insurance company under the applicable laws and regulations. Pursuant to these laws and regulations, EIC must file quarterly and annual reports with the National Association of Insurance Commissioners (“NAIC”) and certain state regulators, must maintain certain minimum amounts of capital and surplus under formulas established by certain states and must, in certain circumstances, request and receive the approval of certain state regulators before making dividend payments or other capital distributions to the Company. The Company does not believe these limitations on dividends and distributions materially impact its financial position. EIC is subject to minimum capital and surplus requirements in certain states. The minimum amount of capital and surplus required to satisfy regulatory requirements in these states is $24,573 as of June 30, 2019. EIC was in excess of the minimum required amounts in these states as of August 31, 2019.

The Company has recorded estimates of various assets and liabilities arising from its participation in the Medicare Part D program based on information in its claims management and enrollment systems. Significant estimates arising from its participation in this program include: (i) estimates of low-income cost subsidies, reinsurance amounts, and coverage gap discount amounts ultimately payable to CMS based on a detailed claims reconciliation that will occur in the following year; (ii) an estimate of amounts receivable from CMS under a risk-sharing feature of the Medicare Part D program design, referred to as the risk corridor and (iii) estimates for claims that have been reported and are in the process of being paid or contested and for our estimate of claims that have been incurred but have not yet been reported.

As of August 31, 2019 and March 2, 2019, accounts receivable, net included $592,278 and $392,400 due from CMS respectively.

9. Manufacturer Rebates Receivables

The Pharmacy Services Segment has manufacturer rebates receivables of $478,869 and $445,200 included in Accounts receivable, net, as of August 31, 2019 and March 2, 2019, respectively.

10. Goodwill and Other Intangible Assets

There was no goodwill impairment charge for the thirteen and twenty-six week periods ended August 31, 2019. At August 31, 2019 and March 2, 2019, accumulated impairment losses for the Pharmacy Services segment was $574,712.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

The Company’s intangible assets are primarily finite-lived and amortized over their useful lives. Following is a summary of the Company’s finite-lived and indefinite-lived intangible assets as of August 31, 2019 and March 2, 2019.


	August 31,2019								March 2, 2019
							Remaining								Remaining
							Weighted								Weighted
	Gross						Average		Gross						Average
	Carrying		Accumulated				Amortization		Carrying		Accumulated				Amortization
	Amount		Amortization		Net		Period		Amount		Amortization		Net		Period
Favorable leases and other(a)	$	182,587	$	(161,096)	$	21,491	3	years	$	370,855	$	(318,503)	$	52,352	7	years
Prescription files		931,050		(848,144)		82,906	3	years		919,749		(827,222)		92,527	3	years
Customer relationships(a)		388,000		(213,837)		174,163	12	years		388,000		(193,352)		194,648	13	years
CMS license		57,500		(9,622)		47,878	21	years		57,500		(8,472)		49,028	22	years
Claims adjudication and other developed software		58,985		(35,245)		23,740	3	years		58,985		(31,030)		27,955	4	years
Trademarks		20,100		(8,409)		11,691	6	years		20,100		(7,404)		12,696	7	years
Backlog		11,500		(11,500)		—	0	years		11,500		(11,500)		—	0	years
Total finite	$	1,649,722	$	(1,287,853)		361,869			$	1,826,689	$	(1,397,483)	$	429,206
Trademarks		19,500		—		19,500	Indefinite			19,500		—		19,500	Indefinite
Total	$	1,669,222	$	(1,287,853)	$	381,369			$	1,846,189	$	(1,397,483)	$	448,706

(a)	Amortized on an accelerated basis which is determined based on the remaining useful economic lives of the customer relationships that are expected to contribute directly or indirectly to future cash flows.

Also included in other non-current liabilities as of August 31, 2019 and March 2, 2019 are unfavorable lease intangibles with a net carrying amount of $0 and $14,763, respectively. In connection with the Adoption of ASU 2016-02, Leases (Topic 842), both favorable and unfavorable leases were reclassified into operating lease right-of-use assets.

Amortization expense for these intangible assets and liabilities was $26,596 and $54,256 for the thirteen and twenty-six week periods ended August 31, 2019, respectively. Amortization expense for these intangible assets and liabilities was $32,500 and $67,900 for the thirteen and twenty-six week periods ended September 1, 2018, respectively The anticipated annual amortization expense for these intangible assets and liabilities is 2020—$100,380; 2021—$78,477; 2022—$58,037; 2023—$42,964 and 2024—$29,386.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

11. Indebtedness and Credit Agreements

Following is a summary of indebtedness and lease financing obligations at August 31, 2019 and March 2, 2019:


	August 31,		March 2,
	2019		2019
Secured Debt:
Senior secured revolving credit facility due December 2023 ($1,250,000 and $875,000 face value less unamortized debt issuance costs of $21,706 and $24,069)	$	1,228,294	$	850,931
FILO term loan due December 2023 ($450,000 face value less unamortized debt issuance costs of $3,458 and $3,918)		446,542		446,082
		1,674,836		1,297,013
Guaranteed Unsecured Debt:
6.125% senior notes due April 2023 ($1,753,490 face value less unamortized debt issuance costs of $14,899 and $16,982)		1,738,591		1,736,508
		1,738,591		1,736,508
Unguaranteed Unsecured Debt:
7.7% notes due February 2027 ($295,000 face value less unamortized debt issuance costs of $1,212 and $1,295)		293,788		293,705
6.875% fixed-rate senior notes due December 2028 ($128,000 face value less unamortized debt issuance costs of $610 and $642)		127,390		127,358
		421,178		421,063
Lease financing obligations		33,244		40,176
Total debt		3,867,849		3,494,760
Current maturities of long-term debt and lease financing obligations		(10,704)		(16,111)
Long-term debt and lease financing obligations, less current maturities	$	3,857,145	$	3,478,649

Credit Facility

On December 20, 2018, the Company entered into a new senior secured credit agreement, consisting of a new $2,700,000 senior secured asset-based revolving credit facility (“Senior Secured Revolving Credit Facility”) and a new $450,000 “first-in, last out” senior secured term loan facility (“Senior Secured Term Loan”) (collectively the “New Facilities”).

Proceeds from the New Facilities were used to refinance the Company’s prior $2,700,000 Amended and Restated Senior Secured Credit Facility due January 2020 (the “Old Facility,” the New Facilities and the Old Facility are collectively referred to herein as the “Facilities”). The New Facilities extend the Company’s debt maturity profile and provide additional liquidity. The New Facilities mature in December 2023, subject to an earlier maturity on December 31, 2022 if the Company has not repaid or refinanced its existing 6.125% Senior Notes due 2023 prior to such date. The Company’s new Senior Secured Revolving Credit Facility will bear interest at a rate of LIBOR plus 125 to 175 basis points (or an alternate base rate plus 25 to 75 basis points), depending on availability under the revolving facility. The Company’s new Senior Secured Term Loan bears interest at a rate of LIBOR plus 300 basis points (or an alternate base rate plus 200 basis points).

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

The Company’s ability to borrow under the New Facilities is based upon a specified borrowing base consisting of accounts receivable, inventory and prescription files. At August 31, 2019, the Company had $1,700,000 of borrowings outstanding under the New Facilities and had letters of credit outstanding against the New Facilities of $83,195 which resulted in additional borrowing capacity of $1,366,805.

The New Facilities restrict the Company and the Subsidiary Guarantors (as defined herein) from accumulating cash on hand in excess of $200,000 at any time revolving loans are outstanding (not including cash located in its stores and lockbox deposit account and cash necessary to cover current liabilities).

The New Facilities allow the Company to have outstanding, at any time, up to $1,500,000 in secured second priority debt, split-priority term loan debt, unsecured debt and disqualified preferred stock in addition to borrowings under the New Facilities and existing indebtedness, provided that not in excess of $750,000 of such secured second priority debt, split-priority term loan debt, unsecured debt and disqualified preferred stock shall mature or require scheduled payments of principal prior to 90 days after the latest of (i) the fifth anniversary of the effectiveness of the New Facilities and (ii) the latest maturity date of any Term Loan or Other Revolving Commitment (each as defined in the New Facilities). Subject to the limitations described in clauses (i) and (ii) of the immediately preceding sentence, the New Facilities additionally allow the Company to issue or incur an unlimited amount of unsecured debt and disqualified preferred stock so long as a Financial Covenant Effectiveness Period (as defined in the New Facilities) is not in effect; provided, however, that certain of the Company’s other outstanding indebtedness limits the amount of unsecured debt that can be incurred if certain interest coverage levels are not met at the time of incurrence or other exemptions are not available. The New Facilities also contain certain restrictions on the amount of secured first priority debt the Company is able to incur. The New Facilities also allow for the voluntary repurchase of any debt or other convertible debt, so long as the New Facilities are not in default and the Company maintains availability under its revolver of more than $365,000.

The New Facilities have a financial covenant that requires the Company to maintain a minimum fixed charge coverage ratio of 1.00 to 1.00 (i) on any date on which availability under the revolver is less than $200,000 or (ii) on the third consecutive business day on which availability under the revolver is less than $250,000 and, in each case, ending on and excluding the first day thereafter, if any, which is the 30th consecutive calendar day on which availability under the New Facilities is equal to or greater than $250,000. As of August 31, 2019, the Company had availability under its New Facilities of $1,366,805, its fixed charge coverage ratio was greater than 1.00 to 1.00, and the Company was in compliance with the New Facilities' financial covenant. The New Facilities also contain covenants which place restrictions on the incurrence of debt, the payments of dividends, sale of assets, mergers and acquisitions and the granting of liens.

The New Facilities also provide for customary events of default.

With the exception of EIC, substantially all of Rite Aid Corporation’s 100 % owned subsidiaries guarantee the obligations under the New Facilities and unsecured guaranteed notes. The New Facilities are secured, on a senior priority basis, by a lien on, among other things, accounts receivable, inventory and prescription files of the Subsidiary Guarantors. The subsidiary guarantees related to the Company’s New Facilities and, on an unsecured basis, the unsecured guaranteed notes, are full and unconditional and joint and several, and there are no restrictions on the ability of the Company to obtain funds from its subsidiaries. The Company has no independent assets or operations. Other than EIC, the subsidiaries, including joint ventures, that do not guarantee the New Facilities and applicable notes, are minor. As such, condensed consolidating financial information for the Company, its guaranteeing subsidiaries and non-

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

guaranteeing subsidiaries is presented for those periods subsequent to the acquisition of EnvisionRx. See Note 17 “Guarantor and Non-Guarantor Condensed Consolidating Financial Information” for additional disclosure.

Fiscal 2019 and 2020 Transactions

On March 13, 2018, the Company issued a notice of redemption for all of the 9.25% Notes that were outstanding on April 12, 2018, pursuant to the terms of the indenture of the 9.25% Notes. On April 12, 2018, the Company redeemed 100% of the remaining outstanding 9.25% Notes. In connection therewith, the Company recorded a loss on debt retirement of $3,422 which included unamortized debt issuance costs, partially offset by unamortized discount. The debt repayment and related loss on debt retirement is included in the results of operations and cash flows of discontinued operations.

On April 19, 2018, the Company announced that it had commenced an offer to purchase up to $700,000 of its outstanding 6.75% Notes and its 6.125% Notes pursuant to the asset sale provisions of such indentures. On May 21, 2018, the Company accepted for payment, pursuant to its offer to purchase, $1,360 aggregate principal amount of the 6.75% Notes and $4,759 aggregate principal amount of the 6.125% Notes. The debt repayment and related loss on debt retirement of $8 for the 6.75% Notes is included in the results of operations and cash flows of discontinued operations. The debt repayment and related loss on debt retirement of $56 for the 6.125% Notes is included in the results of operations and cash flows of continuing operations.

On April 29, 2018, the Company further reduced the borrowing capacity on its Old Facility from $3,000,000 to $2,700,000. In connection therewith, the Company recorded a loss on debt retirement of $1,091, which included unamortized debt issuance costs. The loss on debt retirement is included in the results of operations and cash flows of discontinued operations.

On June 25, 2018, the Company redeemed the remaining $805,169 of its 6.75% Notes, which resulted in a loss on debt retirement of $18,075. The loss on debt retirement is included in the results of operations and cash flows of discontinued operations.

On March 15, 2019, the Company entered into a Cap, which has been assigned to the variable interest rate payments on the first $650,000 notional amount of variable rate indebtedness. The Cap has an effective date of March 21, 2019 and expires on March 21, 2021. The Cap provides the Company with interest rate protection in the event that LIBOR increases above 2.75%.

Maturities

The aggregate annual principal payments of long-term debt for the remainder of fiscal 2020 and thereafter are as follows: 2020—$0; 2021—$0; 2022—$0; 2023—$0; 2024—$3,453,490 and $423,000 thereafter. These aggregate annual principal payments of long-term debt assume that the Company has not repaid or refinanced its existing 6.125% Senior Notes due 2023 prior to December 31, 2022.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

12. Leases

The Company leases most of its retail stores and certain distribution facilities under noncancellable operating and capital leases, most of which have initial lease terms ranging from 5 to 22 years. The Company also leases certain of its equipment and other assets under noncancellable operating leases with initial terms ranging from 3 to 10 years. In addition to minimum rental payments, certain store leases require additional payments based on sales volume, as well as reimbursements for taxes, maintenance and insurance. Most leases contain renewal options, certain of which involve rent increases.

The following table is a summary of the Company’s components of net lease cost for the thirteen and twenty-six week periods ended August 31, 2019:


	Thirteen Week Period		Twenty-Six Week Period
	Ended August 31, 2019		Ended August 31, 2019
Operating lease cost	$	164,002	$	328,985
Financing lease cost:
Amortization of right-of-use asset		1,508		3,044
Interest on long-term finance lease liabilities		856		1,762
Total finance lease costs	$	2,364	$	4,806
Short-term lease costs		115		116
Variable lease costs		42,768		83,314
Less: sublease income		(5,407)		(11,158)
Net lease cost	$	203,842	$	406,063

Supplemental cash flow information related to leases for the twenty-six week period ended August 31, 2019:


	Twenty-Six Week Period
	Ended August 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows paid for operating leases	$	293,884
Operating cash flows paid for interest portion of finance leases		1,762
Financing cash flows paid for principal portion of finance leases		4,453
Right-of-use assets obtained in exchange for lease obligations:
Operating leases		158,463
Finance leases		—

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

Supplemental balance sheet information related to leases as of August 31, 2019 (in thousands, except lease term and discount rate):


	August 31,
	2019
Operating leases:
Operating lease right-of-use asset	$	2,944,651

Short-term operating lease liabilities	$	502,706
Long-term operating lease liabilities		2,745,598
Total operating lease liabilities	$	3,248,304

Finance leases:
Property, plant and equipment, net	$	23,852

Current maturities of long-term debt and lease financing obligations	$	10,704
Lease financing obligations, less current maturities		22,540
Total finance lease liabilities	$	33,244
Weighted average remaining lease term
Operating leases		8.0
Finance leases		8.4

Weighted average discount rate
Operating leases		6.0	%
Finance leases		10.0	%

The following table summarizes the maturity of lease liabilities under finance and operating leases as of August 31, 2019:


	August 31, 2019
	Finance		Operating
Fiscal year	Leases		Leases (1)		Total
2020 (remaining twenty-six weeks)	$	9,482	$	345,844	$	355,326
2021		9,155		645,871		655,026
2022		4,275		579,569		583,844
2023		3,983		524,643		528,626
2024		3,711		462,675		466,386
Thereafter		18,660		1,594,345		1,613,005
Total lease payments		49,266		4,152,947		4,202,213
Less: imputed interest		(16,022)		(904,643)		(920,665)
Total lease liabilities	$	33,244	$	3,248,304	$	3,281,548

(1)	– Future operating lease payments have not been reduced by minimum sublease rentals of $53 million due in the future under noncancelable leases.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

Following are the minimum lease payments for all properties under a lease agreement that will have to be made in each of the years indicated based on non-cancelable leases in effect as of March 2, 2019:


	Lease
	Financing		Operating
Fiscal year	Obligations		Leases
2020	$	19,300	$	687,412
2021		4,811		610,874
2022		4,588		545,863
2023		4,383		490,864
2024		4,042		431,714
Later years		20,470		1,541,408
Total minimum lease payments		57,594	$	4,308,135
Amount representing interest		(17,418)
Present value of minimum lease payments	$	40,176

During the thirteen and twenty-six week periods ended August 31, 2019 and September 1, 2018, the Company did not enter into any sale-leaseback transactions whereby the Company sold owned operating stores to independent third parties and concurrent with the sale, entered into an agreement to lease the store back from the purchasers.

13. Stock Options and Stock Awards

The Company recognizes share-based compensation expense over the requisite service period of the award, net of an estimate for the impact of forfeitures. Operating results for the twenty-six week periods ended August 31, 2019 and September 1, 2018 include $10,092 and $10,246, respectively, of compensation costs related to the Company’s stock-based compensation arrangements.

During fiscal 2018, the Company issued performance units to certain of its associates. The performance units will be settled in cash based on the actual performance of the Company relative to certain financial performance goals and the stock price upon vesting. During the twenty-six week periods ended August 31, 2019 and September 1, 2018, the Company incurred a benefit of $348 compared to expense of $1,724 related to these performance based incentive plans, respectively, which is recorded as a component of stock-based compensation expense.

The total number and type of newly awarded grants and the related weighted average fair value for the twenty-six week periods ended August 31, 2019 and September 1, 2018 are as follows:


	August 31, 2019			September 1, 2018
	Shares	Weighted Average Fair Value		Shares	Weighted Average Fair Value
Stock options granted	503	$	3.54	—	$	N/A
Restricted stock awards granted	1,232	$	7.60	25	$	33.40
Total awards	1,735			25

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

Typically, stock options granted vest, and are subsequently exercisable in equal annual installments over a four-year period for employees. Restricted stock awards typically vest in equal annual installments over a three-year period.

The Company calculates the fair value of stock options using the Black- Scholes-Merton option pricing model.

As of August 31, 2019, the total unrecognized pre-tax compensation costs related to unvested stock options and restricted stock awards granted, net of estimated forfeitures and the weighted average period of cost amortization are as follows:


	August 31, 2019
	Unvested		Unvested		Unvested
	stock		restricted		performance
	options		stock		shares
Unrecognized pre-tax costs	$	1,743	$	16,518	$	246
Weighted average amortization period		3.9 years		2.2 years		0.5 years

14. Retirement Plans

Net periodic pension expense recorded in the thirteen and twenty-six week periods ended August 31, 2019 and September 1, 2018, for the Company’s defined benefit plan includes the following components:


	Defined Benefit				Defined Benefit
	Pension Plan				Pension Plan
	Thirteen Week Period Ended				Twenty-Six Week Period Ended
	August 31,		September 1,		August 31,		September 1,
	2019		2018		2019		2018
Service cost	$	143	$	312	$	285	$	624
Interest cost		1,556		1,578		3,111		3,156
Expected return on plan assets		(1,214)		(1,435)		(2,427)		(2,869)
Amortization of unrecognized prior service cost		—		—		—		—
Amortization of unrecognized net loss		415		507		830		1,015
Net periodic pension expense	$	900	$	962	$	1,799	$	1,926

During the thirteen and twenty-six week periods ended August 31, 2019 the Company contributed $0 and $0, respectively, to the Defined Benefit Pension Plan. During the remainder of fiscal 2020, the Company expects to contribute $0 to the Defined Benefit Pension Plan.

15. Segment Reporting

The Company has two reportable segments, its retail drug stores (“Retail Pharmacy”), and its pharmacy services (“Pharmacy Services”) segments, collectively the “Parent Company”.

The Retail Pharmacy segment’s primary business is the sale of prescription drugs and related consultation to its customers. Additionally, the Retail Pharmacy segment sells a full selection of health and beauty aids and personal care

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

products, seasonal merchandise and a large private brand product line. The Pharmacy Services segment offers a full range of pharmacy benefit management services including plan design and administration, on both a transparent pass-through model and traditional model, formulary management and claims processing. Additionally, the Pharmacy Services segment offers specialty and mail order services, infertility treatment, and drug benefits to eligible beneficiaries under the federal government’s Medicare Part D program.

The Parent Company’s chief operating decision makers are its Parent Company Chief Executive Officer, Chief Operating Officer, Chief Financial Officer, Chief Operating Officer-Retail Pharmacy, and the Chief Executive Officer—Pharmacy Services, (collectively the “CODM”). The CODM has ultimate responsibility for enterprise decisions. The CODM determines, in particular, resource allocation for, and monitors performance of, the consolidated enterprise, the Retail Pharmacy segment and the Pharmacy Services segment. The Retail Pharmacy and Pharmacy Services segment managers have responsibility for operating decisions, allocating resources and assessing performance within their respective segments. The CODM relies on internal management reporting that analyzes enterprise results on certain key performance indicators, namely, revenues, gross profit, and Adjusted EBITDA.

The following is balance sheet information for the Company’s reportable segments:


	Retail		Pharmacy
	Pharmacy		Services		Eliminations(1)		Consolidated
August 31, 2019:
Total Assets	$	8,040,905	$	2,646,710	$	(14,402)	$	10,673,213
Goodwill		43,492		1,064,644		—		1,108,136
March 2, 2019:
Total Assets	$	5,071,055	$	2,534,771	$	(14,459)	$	7,591,367
Goodwill		43,492		1,064,644		—		1,108,136

(1)

As of August 31, 2019 and March 2, 2019, intersegment eliminations include netting of the Pharmacy Services segment long-term deferred tax liability of $0 against the Retail Pharmacy segment long-term deferred tax asset for consolidation purposes in accordance with ASC 740, and intersegment accounts receivable of $14,402 and $14,459, respectively, that represents amounts owed from the Pharmacy Services segment to the Retail Pharmacy segment that are created when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

The following table is a reconciliation of the Company’s business segments to the consolidated financial statements for the thirteen and twenty-six week periods ended August 31, 2019 and September 1, 2018:


	Retail		Pharmacy		Intersegment
	Pharmacy		Services		Eliminations(1)		Consolidated
Thirteen Week Period Ended
August 31, 2019:
Revenues	$	3,848,104	$	1,579,069	$	(60,909)	$	5,366,264
Gross Profit		1,032,444		111,995		—		1,144,439
Adjusted EBITDA(2)		92,673		41,517		—		134,190
Additions to property and equipment and intangible assets		43,328		7,249		—		50,577
September 1, 2018:
Revenues	$	3,911,512	$	1,561,811	$	(51,961)	$	5,421,362
Gross Profit		1,051,637		109,514		—		1,161,151
Adjusted EBITDA(2)		103,618		44,963		—		148,581
Additions to property and equipment and intangible assets		47,302		4,156		—		51,458
Twenty-Six Week Period Ended
August 31, 2019:
Revenues	$	7,712,912	$	3,145,361	$	(119,420)	$	10,738,853
Gross Profit		2,062,939		208,223		—		2,271,162
Adjusted EBITDA(2)		176,681		67,856		—		244,537
Additions to property and equipment and intangible assets		87,572		12,196		—		99,768
September 1, 2018:
Revenues	$	7,809,277	$	3,104,573	$	(103,998)	$	10,809,852
Gross Profit		2,121,094		208,806		—		2,329,900
Adjusted EBITDA(2)		207,747		78,826		—		286,573
Additions to property and equipment and intangible assets		105,369		7,715		—		113,084

(1)

Intersegment eliminations include intersegment revenues and corresponding cost of revenues that occur when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. When this occurs, both the Retail Pharmacy and Pharmacy Services segments record the revenue on a stand-alone basis.

(2)	See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” in MD&A for additional details.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

The following is a reconciliation of net loss to Adjusted EBITDA for the thirteen and twenty-six week periods ended August 31, 2019 and September 1, 2018:


	August 31,		September 1,		August 31,		September 1,
	2019		2018		2019		2018
	(13 weeks)		(13 weeks)		(26 weeks)		(26 weeks)(a)
Net loss from continuing operations	$	(78,705)	$	(352,348)	$	(178,044)	$	(394,075)
Interest expense		60,102		56,233		118,372		119,025
Income tax expense (benefit)		27,628		(106,559)		35,002		(116,056)
Depreciation and amortization		83,044		89,743		166,970		184,272
LIFO charge		7,504		3,358		14,993		13,324
Lease termination and impairment charges		1,471		39,609		1,949		49,468
Goodwill and intangible asset impairment charges		—		375,190		—		375,190
Loss on debt retirements, net		—		—		—		554
Merger and Acquisition-related costs		514		19,031		3,599		26,219
Stock-based compensation expense		4,712		5,215		10,092		10,246
Restructuring-related costs		25,145		—		68,495		—
Inventory write-downs related to store closings		3,149		1,300		3,990		5,133
Litigation settlement		—		18,000		—		18,000
Gain on sale of assets, net		(1,587)		(4,965)		(4,299)		(10,824)
Other		1,213		4,774		3,418		6,097
Adjusted EBITDA from continuing operations	$	134,190	$	148,581	$	244,537	$	286,573

(a) During fiscal 2019, the Company revised its definition of Adjusted EBITDA to no longer exclude the impact of revenue deferrals related to our customer loyalty program and further revised its disclosure by presenting certain amounts previously included within Other as separate reconciling items. Consequently, the Company revised Adjusted EBITDA for the thirteen and twenty-six week periods ended September 1, 2018 to conform with the revised definition and present separate reconciling items previously included with Other.

16. Commitments, Contingencies and Guarantees

Legal Matters and Regulatory Proceedings

The Company is involved in legal matters including litigation, arbitration, and other claims, and is subject to regulatory proceedings including investigations, inspections, audits, inquiries, and similar actions by pharmacy, health care, tax and other governmental authorities arising in the ordinary course of its business, including, without limitation, the matters described below. The Company records accruals for outstanding legal matters and applicable regulatory proceedings when it believes it is probable that a loss has been incurred, and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters and regulatory proceedings that could affect the amount of any existing accrual and developments that would make a loss contingency both probable and reasonably estimable, and as a result, warrant an accrual. If a loss contingency is not both probable and estimable, the Company

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

does not establish an accrued liability. None of the Company’s accruals for outstanding legal matters or regulatory proceedings are material individually or in the aggregate to the Company’s consolidated financial position.

The Company’s contingencies are subject to significant uncertainties, many of which are beyond the Company’s control, including, among other factors: (i) proceedings are in early stages; (ii) whether class or collective action status is sought and the likelihood of a class being certified; (iii) the outcome of pending appeals or motions; (iv) the extent of potential damages, fines or penalties, which are often unspecified or indeterminate; (v) the impact of discovery on the matter; (vi) whether novel or unsettled legal theories are at issue; (vii) there are significant factual issues to be resolved; and/or (viii) in the case of certain government agency investigations, whether a qui tam lawsuit (“whistleblower” action) has been filed and whether the government agency makes a decision to intervene in the lawsuit following investigation. While the Company cannot predict the outcome of any of the contingencies, the Company’s management does not believe that the outcome of any of these legal matters or regulatory proceedings will be material to the Company’s consolidated financial position. It is possible, however, the Company’s results of operations or cash flows could be materially affected by unfavorable outcomes in outstanding legal matters or regulatory proceedings.

The Company is currently a defendant in several lawsuits filed in courts in California alleging violations of California Business and Professions Code, industry wage orders, wage-and-hour laws, rules and regulations pertaining primarily to failure to pay overtime, failure to pay for missed meals and rest periods, and failure to reimburse business expenses (the “California Cases”). Some of the California Cases purport or may be determined to be class actions or PAGA representative actions and seek substantial damages and penalties. The single-plaintiff and multi-plaintiff California Cases regarding violations of wage-and-hour laws, failure to pay overtime, failure to pay for missed meals and rest periods, and failure to reimburse business expenses, in the aggregate, seek substantial damages. The Company believes that its defenses and assertions in the California Cases, as well as other lawsuits, have merit. The Company has aggressively challenged the merits of the lawsuits and, where applicable, the allegations that the lawsuits should be certified as class or representative actions. Additionally, at this time the Company is not able to predict either the outcome of or estimate a potential range of loss with respect to the California Cases and is vigorously defending them.

Following service of subpoenas on the Company in 2011 and 2013 by the United States Attorney’s Office for the Eastern District of Michigan (“USAO”) and the State of Indiana’s Office of the Attorney General, respectively, the Company cooperated with inquiries regarding the relationship of Rite Aid’s Rx Savings Program to the reporting of usual and customary charges to publicly funded health programs. In January 2017, the USAO, 18 states and the District of Columbia declined to intervene in a sealed False Claims Act (“FCA”) lawsuit filed by qui tam plaintiff Azam Rahimi (“Relator”) in the District Court for the Eastern District of Michigan. On January 19, 2017, the court unsealed Relator’s Second Amended Complaint against the Company; it alleges that the Company failed to report Rx Savings prices as its usual and customary charges under the Medicare Part D program and to federal and state Medicaid programs in 18 states and the District of Columbia; and that the Company is thus liable under the federal FCA and similar state statutes. In its ruling on the Company’s motion to dismiss the complaint, the Court held that Relator’s complaint was deficient, but allowed Relator the opportunity to re-plead. Relator filed a Third Amended Complaint on May 11, 2018. The Company filed a motion to dismiss the Third Amended Complaint on May 25, 2018. On March 30, 2019, the Company’s motion to dismiss the Third Amended Complaint was denied. The court entered a scheduling order on May 29, 2019, and the case is proceeding through discovery. On July 31, 2019, Rite Aid filed a motion to dismiss and for judgment on the pleadings based on the False Claims Act’s public disclosure bar. Relator’s opposition to the motion is due on September 11, 2019, and Rite Aid’s reply is due on October 9, 2019. At this stage of the proceedings, the Company is not able to either predict the outcome of this lawsuit or estimate a potential range of loss with respect to the lawsuit and is vigorously defending this lawsuit.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

On April 26, 2012, the Company was served with an administrative subpoena from the U.S. Drug Enforcement Administration (“DEA”), Albany, New York District Office, requesting information regarding the Company’s sale of products containing pseudoephedrine (“PSE”). In April 2012, it also received a communication from the U.S. Attorney’s Office for the Northern District of New York (“USAO”) regarding an investigation of possible civil violations of the Combat Methamphetamine Epidemic Act of 2005 (“CMEA”). Additional subpoenas were served in 2013, 2014, and 2015 requesting broader documentation regarding PSE sales and recordkeeping requirements. Assistant U.S. Attorneys from the Northern and Eastern Districts of New York are currently investigating, but no lawsuits have been filed. Civil violations of the CMEA could result in the imposition of administrative and/or civil penalties against the Company. The Company has entered into tolling agreements with the United States, and discussions have been held to attempt to resolve these matters with those USAOs and the Department of Justice, but whether any agreements can be reached and on what terms is uncertain. At this stage of the investigation, the Company is not able to predict the outcome of the investigation.

In December 2017, Rite Aid executed a non-prosecution agreement with the United States Attorney’s Office for the Southern District of West Virginia (countersigned by the government in January 2018), which concluded the criminal investigation into Rite Aid’s PSE sales. Pursuant to the non-prosecution agreement, the government agreed not to bring any criminal charges against Rite Aid and Rite Aid agreed to pay an immaterial amount of money as restitution. The civil investigation is ongoing.

In June 2013, the Company was served with a Civil Investigative Demand (“CID”) by the United States Attorney’s Office for the Eastern District of California (the “USAO”) regarding (1) the Company’s Drug Utilization Review (“DUR”) and prescription dispensing protocol; and (2) the dispensing of drugs designated as “Code 1” by the State of California. The Company cooperated with the investigation, researched the government’s allegations, and refuted the government’s position. The Company produced documents including certain prescription files related to Code 1 drugs to the USAO’s office and the State of California Department of Justice’s Bureau of Medical Fraud and Elder Abuse (“CADOJ”). In August 2014, the USAO and 8 states’ attorneys general declined to intervene in a California False Claim Act (“FCA”) action (“Action”) filed under seal in the Eastern District of California by qui tam plaintiff Loyd F. Schmuckley (“Relator”) based on DUR and Code 1 allegations. In July 2016, the Commonwealth of Massachusetts and the District of Columbia also declined to intervene in the Action. On May 15, 2017, Relator and the CADOJ stipulated to dismiss all DUR-related claims and 18 other state-based claims. On September 21, 2017, the CADOJ filed a sealed complaint-in-intervention in the Action, asserting causes under the FCA, for unjust enrichment and for payment by mistake related to the Code 1 allegations. The Action was unsealed on September 26, 2017. On September 28, 2017, Relator filed a First Amended Complaint under the FCA also concerning the Code 1 allegations. The Company filed a motion to dismiss Relator’s and CADOJ’s respective complaints in January 2018, the hearing was held on March 23, 2018. On September 5, 2018, the court issued an order denying the motion to dismiss. The case was divided into phases, with the first phase focused upon plaintiffs’ proposed sampling methodology for determining liability and damages. Following fact and expert discovery, the Company’s motion challenging plaintiffs’ proposed sampling methodology was heard on July 15, 2019. Supplemental briefing was requested by the Court and filed on July 29, 2019, and to date, no decision has been rendered. At this stage of the proceedings, the Company is not able to either predict the outcome of this matter or estimate a potential range of loss with respect to this matter, and is vigorously defending this lawsuit.

The State of Mississippi, by and through its Attorney General, filed a First Amended Complaint (Complaint”) against the Company and various purported related entities on September 27, 2016 alleging violations of the Mississippi

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

Medicaid Fraud Control Act, violations of the Mississippi Unfair and Deceptive Trade Practices Act, fraud and unjust enrichment. The Complaint alleges the Company failed to accurately report usual and customary prices to Mississippi’s Division of Medicaid. On November 14, 2016, the Company filed motions to dismiss based on jurisdictional and substantive grounds, as well as a motion to transfer venue, all of which were stayed pending the resolution of related litigation involving another chain pharmacy on appeal. In September 2018, the stay of the case was lifted. On November 28, 2018, the case was transferred to the Circuit Court of Desoto County and consolidated with related cases containing similar allegations brought by Mississippi against other chain pharmacies. On June 11, 2019, the court (i) dismissed the claims against the Company for lack of personal jurisdiction; and (ii) dismissed the fraud-based claims against the Company’s purportedly related entities (Rite Aid Hdqtrs. Corp., Harco, Inc., and K&B of Mississippi Corporation) for failure to plead the fraud-based claims with particularity, but with leave to amend. The court did not dismiss the claims against the purportedly related entities for unjust enrichment or for restitution under the Mississippi Consumer Protection Act. On August 2, 2019, the State of Mississippi filed a Second Amended Complaint that does not assert any claims against the Company, but does assert claims against the purportedly related entities for fraud, unjust enrichment, and for restitution under the Mississippi Consumer Protection Act. At this stage of the proceedings, the Company is not able to either predict the outcome of this lawsuit or estimate a potential range of loss with respect to the lawsuit, and is vigorously defending this lawsuit.

The Company is named in multiple opioid-related lawsuits filed by counties, cities, municipalities, Native American tribes, hospitals, and third-party payers across the United States. Specifically, as of September 24, 2019, a total of 1,262 opioid-related lawsuits have been filed against the Company. 1,104 lawsuits have been filed in federal court, of which 1,018 have been transferred to the multi-district litigation (“MDL”) pending in the U.S. District Court for the Northern District of Ohio before Judge Dan Polster under In re National Prescription Opiate Litigation (Case No. 17-MD-2804). There are approximately 158 lawsuits that name the Company in some capacity that have been filed outside the MDL in state court. The plaintiffs in all of these opioid-related lawsuits generally allege claims concerning the impacts of widespread opioid abuse against defendants along the pharmaceutical supply chain, including manufacturers, wholesale distributors, and retail pharmacies.

New lawsuits continue to be added to the MDL, including lawsuits filed in Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. Since December 2017, nearly all related lawsuits pending in federal district courts have been transferred to the MDL. Two of the Ohio lawsuits in the MDL (referred to as the “Track One” or “bellwether” lawsuits) have been set for an October 21, 2019 trial date: The County of Summit, Ohio v. Purdue Pharma L.P., et al., Case No. 18-OP-45090 (N.D. Ohio); and The County of Cuyahoga v. Purdue Pharma L.P., et al., Case No. 17-OP-45004 (N.D. Ohio). On August 15, 2019, Judge Polster granted the plaintiffs’ motion to sever several defendants, including the Company. As a result, the Company will not be a defendant in the first bellwether trial, but could be a defendant in a subsequent trial involving the same plaintiffs. A group of West Virginia lawsuits have already been selected for the second bellwether track, which include lawsuits filed by Cabell and Huntington Counties.

The federal lawsuits that are not part of the MDL are filed by counties and municipalities in California, Georgia, Idaho, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, New Jersey, New York, North Dakota, Oklahoma, Pennsylvania, Utah, Vermont, Virginia, and West Virginia. The lawsuits filed outside the MDL in state

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

courts include lawsuits filed by counties and municipalities in Connecticut, Delaware, Georgia, Idaho, Illinois, Louisiana, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Tennessee, Washington, and West Virginia.

At this stage of the proceedings, the Company is not able to predict the outcome of the opioid-related lawsuits or estimate a potential range of loss regarding the lawsuits. However, the Company has and will continue to vigorously defend itself against all opioid-related lawsuits. Additionally, the Company is also responding to subpoenas, civil investigative demands, and/or other requests regarding opioids that it has received from the Attorney Generals of several states.

The Company is involved in two putative consumer class action lawsuits in the United States District Court for the Southern District of California, alleging that it overcharged customers’ insurance companies for prescription drug purchases, resulting in overpayment of co-pays. The first lawsuit, Byron Stafford v. Rite Aid Corp., Case No. 17-CV-01340-AJB-JLB, was filed on June 30, 2017, and the second case, Robert Josten v. Rite Aid Corp., Case No. 18-CV-00152-AJB-JLB, was filed on January 23, 2018. Each lawsuit alleges that (i) the Company was obligated to charge the plaintiffs’ insurance companies a “usual and customary” price for their prescription drugs; and (ii) the Company failed to do so properly because the prices it reported were not equal to or adjusted to account for the prices that Rite Aid offers to uninsured and underinsured customers through its Rx Savings Program.

On December 19, 2017, the court granted the Company’s motion to dismiss Stafford’s complaint with leave to amend for failure to plead compliance with the applicable statutes of limitations. After Stafford amended the complaint on January 9, 2018, the Company filed another motion to dismiss on January 23, 2018. The Court denied that motion and opened discovery. Stafford’s deadline to file his class certification motion is December 11, 2019. On June 17, 2019, Rite Aid filed a motion to compel all Stafford’s claims to an individual arbitration and an accompanying motion to stay the entire action pending the court’s decision on its motion to compel arbitration. The court took the motion to compel arbitration under consideration for decision without a hearing, but denied the motion to stay the case pending a decision on that motion.

Rite Aid moved to dismiss Josten’s complaint on March 16, 2018. The court granted the motion to dismiss most of Josten’s claims for failure to plead compliance with the applicable statute of limitations but with leave to amend. The Company moved to dismiss Josten’s amended complaint on the grounds that the statute of limitations expired and that he failed to exhaust Medicare administrative remedies. The court denied that motion on August 7, 2019. A case management conference is scheduled for September 24, 2019, where the court will likely set a pretrial schedule, including with respect to discovery and class certification.

At this stage of the proceedings, the Company is not able to either predict the outcome of the Stafford or Josten lawsuits or estimate a potential range of loss with respect to the lawsuits and is vigorously defending these lawsuits.

In addition to the above described matters, the Company is subject from time to time to various claims and lawsuits and governmental investigations arising in the ordinary course of business. While the Company’s management cannot predict the outcome of any of the claims, the Company’s management does not believe that the outcome of any of these matters will be material to the Company’s consolidated financial position. It is possible, however, that the Company’s results of operations or cash flows could be materially affected by an unfavorable resolution of pending litigation or contingencies.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

17. Guarantor and Non-Guarantor Condensed Consolidating Financial Information

Rite Aid Corporation conducts the majority of its business through its subsidiaries. With the exception of EIC, substantially all of Rite Aid Corporation’s 100% owned subsidiaries guarantee the obligations under the New Facilities and unsecured guaranteed notes (the “Subsidiary Guarantors”). Additionally, with the exception of EIC, the subsidiaries, including joint ventures, that do not guarantee the New Facilities and unsecured guaranteed notes, are minor.

For the purposes of preparing the information below, Rite Aid Corporation uses the equity method to account for its investment in subsidiaries. The equity method has been used by Subsidiary Guarantors with respect to investments in the non-guarantor subsidiaries. The subsidiary guarantees related to the Company’s New Facilities and, on an unsecured basis, the unsecured guaranteed notes, are full and unconditional and joint and several. Presented below is condensed consolidating financial information for Rite Aid Corporation, the Subsidiary Guarantors, and the non-guarantor subsidiaries at August 31, 2019, March 2, 2019 and for the thirteen and twenty-six week periods ended August 31, 2019 and September 1, 2018. Separate financial statements for Subsidiary Guarantors are not presented.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)


	Rite Aid Corporation
	Condensed Consolidating Balance Sheet
	August 31, 2019
	(unaudited)
	Rite Aid
	Corporation				Non-
	(Parent		Subsidiary		Guarantor
	Company Only)		Guarantors		Subsidiaries		Eliminations			Consolidated
	(in thousands)
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	122,321	$	19,860	$	—		$	142,181
Accounts receivable, net		—		1,349,635		595,965		—			1,945,600
Intercompany receivable		—		563,908		—		(563,908)	(a)		—
Inventories, net of LIFO reserve of $0, $619,437, $0, $0, and $619,437		—		1,968,937		—		—			1,968,937
Prepaid expenses and other current assets		—		180,331		3,097		—			183,428
Current assets held for sale		—		145,213		—		—			145,213
Total current assets		—		4,330,345		618,922		(563,908)			4,385,359
Property, plant and equipment, net		—		1,270,467		—		—			1,270,467
Operating lease right-of-use assets		—		2,944,651		—		—			2,944,651
Goodwill		—		1,108,136		—		—			1,108,136
Other intangibles, net		—		333,491		47,878		—			381,369
Deferred tax assets		10,828		381,315		(10,038)		—			382,105
Investment in subsidiaries		8,171,685		57,488		—		(8,229,173)	(b)		—
Intercompany receivable		—		3,372,868		—		(3,372,868)	(a)		—
Other assets		46		194,136		6,944		—			201,126
Total assets	$	8,182,559	$	13,992,897	$	663,706	$	(12,165,949)		$	10,673,213
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current maturities of long-term debt and lease financing obligations	$	—	$	10,704	$	—	$	—		$	10,704
Accounts payable		—		1,560,560		9,618		—			1,570,178
Intercompany payable		—		—		563,908		(563,908)	(a)		—
Accrued salaries, wages and other current liabilities		14,500		693,595		24,692		—			732,787
Current portion of operating lease liabilities		—		502,706		—		—			502,706
Current liabilities held for sale		—		43,364		—		—			43,364
Total current liabilities		14,500		2,810,929		598,218		(563,908)			2,859,739
Long-term debt, less current maturities		3,834,605		—		—		—			3,834,605
Long-term operating lease liabilities		—		2,745,598		—		—			2,745,598
Lease financing obligations, less current maturities		—		22,540		—		—			22,540
Intercompany payable		3,372,868		—		—		(3,372,868)	(a)		—
Other noncurrent liabilities		—		242,145		8,000		—			250,145
Total liabilities		7,221,973		5,821,212		606,218		(3,936,776)			9,712,627
Commitments and contingencies		—		—		—		—			—
Total stockholders’ equity		960,586		8,171,685		57,488		(8,229,173)	(b)		960,586
Total liabilities and stockholders’ equity	$	8,182,559	$	13,992,897	$	663,706	$	(12,165,949)		$	10,673,213

(a)	Elimination of intercompany accounts receivable and accounts payable amounts.

(b)	Elimination of investments in consolidated subsidiaries.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)


	Rite Aid Corporation
	Condensed Consolidating Balance Sheet
	March 2, 2019
	Rite Aid
	Corporation				Non-
	(Parent		Subsidiary		Guarantor
	Company Only)		Guarantors		Subsidiaries		Eliminations			Consolidated
		(in thousands)
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	122,134	$	22,219	$	—		$	144,353
Accounts receivable, net		—		1,377,342		411,370		—			1,788,712
Intercompany receivable		—		400,526		—		(400,526)	(a)		—
Inventories, net of LIFO reserve of $0, $604,444, $0, $0, and $604,444		—		1,871,941		—		—			1,871,941
Prepaid expenses and other current assets		—		172,448		6,684		—			179,132
Current assets held for sale		—		117,581		—		—			117,581
Total current assets		—		4,061,972		440,273		(400,526)			4,101,719
Property, plant and equipment, net		—		1,308,514		—		—			1,308,514
Goodwill		—		1,108,136		—		—			1,108,136
Other intangibles, net		—		399,678		49,028		—			448,706
Deferred tax assets		—		419,122		(10,038)		—			409,084
Investment in subsidiaries		8,294,315		55,109		—		(8,349,424)	(b)		—
Intercompany receivable		—		3,639,035		—		(3,639,035)	(a)		—
Other assets		—		208,018		7,190		—			215,208
Total assets	$	8,294,315	$	11,199,584	$	486,453	$	(12,388,985)		$	7,591,367
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current maturities of long-term debt and lease financing obligations	$	—	$	16,111	$	—	$	—		$	16,111
Accounts payable		—		1,612,181		6,404		—			1,618,585
Intercompany payable		—		—		400,526		(400,526)	(a)		—
Accrued salaries, wages and other current liabilities		14,005		778,020		16,414		—			808,439
Total current liabilities		14,005		2,406,312		423,344		(400,526)			2,443,135
Long-term debt, less current maturities		3,454,585		—		—		—			3,454,585
Lease financing obligations, less current maturities		—		24,064		—		—			24,064
Intercompany payable		3,639,035		—		—		(3,639,035)	(a)		—
Other noncurrent liabilities		—		474,893		8,000		—			482,893
Total liabilities		7,107,625		2,905,269		431,344		(4,039,561)			6,404,677
Commitments and contingencies		—		—		—		—			—
Total stockholders’ equity		1,186,690		8,294,315		55,109		(8,349,424)	(b)		1,186,690
Total liabilities and stockholders’ equity	$	8,294,315	$	11,199,584	$	486,453	$	(12,388,985)		$	7,591,367

(a)	Elimination of intercompany accounts receivable and accounts payable amounts.

(b)	Elimination of investments in consolidated subsidiaries.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)


	Rite Aid Corporation
	Condensed Consolidating Statement of Operations
	Thirteen Week Period Ended August 31, 2019
	(unaudited)
	Rite Aid
	Corporation				Non-
	(Parent		Subsidiary		Guarantor
	Company Only)		Guarantors		Subsidiaries		Eliminations			Consolidated
		(in thousands)
Revenues	$	—	$	5,268,112	$	103,167	$	(5,015)	(a)	$	5,366,264
Costs and expenses:
Cost of revenues		—		4,131,064		95,679		(4,918)	(a)		4,221,825
Selling, general and administrative expenses		—		1,129,058		6,569		(97)	(a)		1,135,530
Lease termination and impairment charges		—		1,471		—		—			1,471
Interest expense		56,863		3,404		(165)		—			60,102
Gain on sale of assets, net		—		(1,587)		—		—			(1,587)
Equity in earnings of subsidiaries, net of tax		22,416		(1,084)		—		(21,332)	(b)		—
		79,279		5,262,326		102,083		(26,347)			5,417,341
(Loss) income from continuing operations before income taxes		(79,279)		5,786		1,084		21,332			(51,077)
Income tax expense		—		27,628		—		—			27,628
Net (loss) income from continuing operations	$	(79,279)	$	(21,842)	$	1,084	$	21,332		$	(78,705)
Net loss from discontinued operations		—		(574)		—		—			(574)
Net (loss) income		(79,279)		(22,416)		1,084		21,332	(b)		(79,279)
Total other comprehensive income (loss)		398		415		—		(415)			398
Comprehensive (loss) income	$	(78,881)	$	(22,001)	$	1,084	$	20,917		$	(78,881)

(a)	Elimination of intercompany revenues and expenses.

(b)	Elimination of equity in earnings of subsidiaries.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)


	Rite Aid Corporation
	Condensed Consolidating Statement of Operations
	Thirteen Week Period Ended September 1, 2018
	(unaudited)
	Rite Aid
	Corporation				Non-
	(Parent		Subsidiary		Guarantor
	Company Only)		Guarantors		Subsidiaries		Eliminations			Consolidated
	(in thousands)
Revenues	$	—	$	5,347,051	$	101,900	$	(27,589)	(a)	$	5,421,362
Costs and expenses:
Cost of revenues		—		4,193,129		94,470		(27,388)	(a)		4,260,211
Selling, general and administrative expenses		—		1,147,491		6,701		(201)	(a)		1,153,991
Lease termination and impairment charges		—		39,609		—		—			39,609
Goodwill and intangible asset impairment charges		—		375,190		—		—			375,190
Interest expense		52,365		3,811		57		—			56,233
Gain on sale of assets, net		—		(4,965)		—		—			(4,965)
Equity in earnings of subsidiaries, net of tax		288,700		(852)		—		(287,848)	(b)		—
		341,065		5,753,413		101,228		(315,437)			5,880,269
(Loss) income from continuing operations before income taxes		(341,065)		(406,362)		672		287,848			(458,907)
Income tax benefit		—		(106,379)		(180)		—			(106,559)
Net (loss) income from continuing operations	$	(341,065)	$	(299,983)	$	852	$	287,848		$	(352,348)
Net (loss) income from discontinued operations		(18,075)		11,283		—		—			(6,792)
Net (loss) income		(359,140)		(288,700)		852		287,848	(b)		(359,140)
Total other comprehensive income (loss)		364		364		—		(364)			364
Comprehensive (loss) income	$	(358,776)	$	(288,336)	$	852	$	287,484		$	(358,776)

(a)	Elimination of intercompany revenues and expenses.

(b)	Elimination of equity in earnings of subsidiaries.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)


	Rite Aid Corporation
	Condensed Consolidating Statement of Operations
	Twenty-Six Week Period Ended August 31, 2019
	(unaudited)
	Rite Aid
	Corporation				Non-
	(Parent		Subsidiary		Guarantor
	Company Only)		Guarantors		Subsidiaries		Eliminations			Consolidated
	(in thousands)
Revenues	$	—	$	10,549,436	$	207,588	$	(18,171)	(a)	$	10,738,853
Costs and expenses:
Cost of revenues		—		8,293,206		192,462		(17,977)	(a)		8,467,691
Selling, general and administrative expenses		—		2,285,284		13,092		(194)	(a)		2,298,182
Lease termination and impairment expenses		—		1,949		—		—			1,949
Interest expense		111,818		6,899		(345)		—			118,372
Gain on sale of assets, net		—		(4,299)		—		—			(4,299)
Equity in earnings of subsidiaries, net of tax		67,120		(2,379)		—		(64,741)	(b)		—
		178,938		10,580,660		205,209		(82,912)			10,881,895
(Loss) income before income taxes		(178,938)		(31,224)		2,379		64,741			(143,042)
Income tax expense		—		35,002		—		—			35,002
Net (loss) income from continuing operations		(178,938)		(66,226)		2,379		64,741			(178,044)
Net loss from discontinued operations		—		(894)		—		—			(894)
Net (loss) income	$	(178,938)	$	(67,120)	$	2,379	$	64,741	(b)	$	(178,938)
Total other comprehensive income (loss)		157		157		—		(157)			157
Comprehensive (loss) income	$	(178,781)	$	(66,963)	$	2,379	$	64,584		$	(178,781)

(a)	Elimination of intercompany revenues and expenses.

(b)	Elimination of equity in earnings of subsidiaries.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)


	Rite Aid Corporation
	Condensed Consolidating Statement of Operations
	Twenty-Six Week Period Ended September 1, 2018
	(unaudited)
	Rite Aid
	Corporation				Non-
	(Parent		Subsidiary		Guarantor
	Company Only)		Guarantors		Subsidiaries		Eliminations			Consolidated
	(in thousands)
Revenues	$	—	$	10,668,075	$	197,485	$	(55,708)	(a)	$	10,809,852
Costs and expenses:
Cost of revenues		—		8,351,757		183,502		(55,307)	(a)		8,479,952
Selling, general and administrative expenses		—		2,292,321		14,698		(401)	(a)		2,306,618
Lease termination and impairment expenses		—		49,468		—		—			49,468
Goodwill and intangible asset impairment charges		—		375,190		—					375,190
Interest expense		112,304		6,756		(35)		—			119,025
Loss on debt retirements, net		—		554		—					554
Gain on sale of assets, net		—		(10,824)		—		—			(10,824)
Equity in earnings of subsidiaries, net of tax		9,730		633		—		(10,363)	(b)		—
		122,034		11,065,855		198,165		(66,071)			11,319,983
(Loss) income before income taxes		(122,034)		(397,780)		(680)		10,363			(510,131)
Income tax benefit		—		(116,009)		(47)		—			(116,056)
Net (loss) income from continuing operations		(122,034)		(281,771)		(633)		10,363			(394,075)
Net (loss) income from discontinued operations		(22,690)		272,041		—		—			249,351
Net (loss) income	$	(144,724)	$	(9,730)	$	(633)	$	10,363	(b)	$	(144,724)
Total other comprehensive income (loss)		728		728		—		(728)			728
Comprehensive (loss) income	$	(143,996)	$	(9,002)	$	(633)	$	9,635		$	(143,996)

(a)	Elimination of intercompany revenues and expenses.

(b)	Elimination of equity in earnings of subsidiaries.

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)


	Rite Aid Corporation
	Condensed Consolidating Statement of Cash Flows
	Twenty-Six Week Period Ended August 31, 2019
	(unaudited)
	Rite Aid
	Corporation				Non-
	(Parent		Subsidiary		Guarantor
	Company Only)		Guarantors		Subsidiaries		Eliminations		Consolidated
	(in thousands)
Operating activities:
Net cash used in operating activities	$	(106,302)	$	(221,377)	$	(2,359)	$	—	$	(330,038)
Investing activities:
Payments for property, plant and equipment		—		(84,060)		—		—		(84,060)
Intangible assets acquired		—		(15,708)		—		—		(15,708)
Intercompany activity		—		271,864		—		(271,864)		—
Proceeds from dispositions of assets and investments		—		4,423		—		—		4,423
Net cash provided by (used in) investing activities		—		176,519		—		(271,864)		(95,345)
Financing activities:
Net proceeds from revolver		375,000		—		—		—		375,000
Principal payments on long-term debt		3,481		(6,932)		—		—		(3,451)
Change in zero balance cash accounts		—		54,712		—		—		54,712
Payments for taxes related to net share settlement of equity awards		—		(986)		—		—		(986)
Deferred financing costs paid		(315)		—		—		—		(315)
Intercompany activity		(271,864)		—		—		271,864		—
Net cash provided by financing activities		106,302		46,794		—		271,864		424,960
Cash flows of discontinued operations:
Operating activities of discontinued operations		—		(2,272)		—		—		(2,272)
Investing activities of discontinued operations		—		523		—		—		523
Financing activities of discontinued operations		—		—		—		—		—
Net cash used in discontinued operations		—		(1,749)		—		—		(1,749)
Increase (decrease) in cash and cash equivalents		—		187		(2,359)		—		(2,172)
Cash and cash equivalents, beginning of period		—		122,134		22,219		—		144,353
Cash and cash equivalents, end of period	$	—	$	122,321	$	19,860	$	—	$	142,181

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)


	Rite Aid Corporation
	Condensed Consolidating Statement of Cash Flows
	Twenty-Six Week Period Ended September 1, 2018
	(unaudited)
	Rite Aid
	Corporation
	(Parent				Non-
	Company		Subsidiary		Guarantor
	Only)		Guarantors		Subsidiaries		Eliminations		Consolidated
	(in thousands)
Operating activities:
Net cash (used in) provided by operating activities	$	(158,413)	$	(165,518)	$	23,029	$	—	$	(300,902)
Investing activities:
Payments for property, plant and equipment		—		(92,565)		—		—		(92,565)
Intangible assets acquired		—		(20,519)		—		—		(20,519)
Intercompany activity		—		(597,415)		—		597,415		—
Proceeds from dispositions of assets and investments		—		15,729		—		—		15,729
Proceeds from sale-leaseback transactions		—		2,587		—		—		2,587
Net cash (used in) provided by investing activities		—		(692,183)		—		597,415		(94,768)
Financing activities:
Net proceeds from revolver		1,335,000		—		—		—		1,335,000
Principal payments on long-term debt		(426,307)		(7,439)		—		—		(433,746)
Change in zero balance cash accounts		—		(17,101)		—		—		(17,101)
Net proceeds from issuance of common stock		1,302		—		—		—		1,302
Payments for taxes related to net share settlement of equity awards		—		(2,244)		—		—		(2,244)
Financing fees paid for early redemption		—		(13)		—		—		(13)
Intercompany activity		597,415		—		—		(597,415)		—
Net cash provided by (used in) financing activities		1,507,410		(26,797)		—		(597,415)		883,198
Cash flows of discontinued operations:
Operating activities of discontinued operations		(4,615)		(57,388)		—		—		(62,003)
Investing activities of discontinued operations		—		603,402		—		—		603,402
Financing activities of discontinued operations		(1,344,382)		589		—		—		(1,343,793)
Net cash (used in) provided by discontinued operations		(1,348,997)		546,603		—		—		(802,394)
(Decrease) increase in cash and cash equivalents		—		(337,895)		23,029		—		(314,866)
Cash and cash equivalents, beginning of period		—		441,244		6,090		—		447,334
Cash and cash equivalents, end of period	$	—	$	103,349	$	29,119	$	—	$	132,468

Table of Contents

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Twenty-Six Week Periods Ended August 31, 2019 and September 1, 2018

(Dollars and share information in thousands, except per share amounts)

(unaudited)

18. Supplementary Cash Flow Data


	Twenty-Six Week Period Ended
	August 31, 2019		September 1, 2018
Cash paid for interest(a)	$	110,401	$	165,995
Cash payments for income taxes, net(a)	$	4,059	$	19,314
Change in operating lease right-of-use assets	$	82,125	$	—
Change in operating lease liabilities	$	(47,143)	$	—
Equipment financed under capital leases	$	2,077	$	2,275
Gross borrowings from revolver(a)	$	1,524,000	$	2,237,000
Gross repayments to revolver(a)	$	1,149,000	$	902,000

(a) — Amounts are presented on a total company basis.

Significant components of cash used in Other Liabilities of $8,104 for the twenty-six week period ended August 31, 2019 includes cash used resulting from a decrease in compensation and benefit related accruals of $44,506 partially offset by an increase in legal, professional and occupancy and the Company’s wellness deferral related accruals of $30,099.

Table of Contents

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations

Overview

We are a pharmacy retail healthcare company, providing our customers and communities with a high level of care and service through various programs we offer through our two reportable business segments, our Retail Pharmacy segment and our Pharmacy Services segment. We accomplish our goal of delivering comprehensive care to our customers through our retail drugstores, RediClinic walk-in retail health clinics and our transparent and traditional PBMs, EnvisionRxOptions and MedTrak. We also offer fully integrated mail-order and specialty pharmacy services through EnvisionPharmacies. Additionally through EIC, EnvisionRxOptions also serves one of the fastest-growing demographics in healthcare: seniors enrolled in Medicare Part D. When combined with our retail platform, this comprehensive suite of services allows us to provide value and choice to customers, patients and payors and allows us to compete in today's evolving healthcare marketplace.

Retail Pharmacy Segment

Our Retail Pharmacy segment sells brand and generic prescription drugs, as well as an assortment of front-end products including health and beauty aids, personal care products, seasonal merchandise, and a large private brand product line. Our Retail Pharmacy segment generates the majority of its revenue through the sale of prescription drugs and front-end products at our 2,464 retail stores. We replenish our retail stores through a combination of direct store delivery of pharmaceutical products facilitated through our pharmaceutical Purchasing and Delivery Agreement with McKesson, and the majority of our front-end products through our network of distribution centers. In addition, the Retail Pharmacy segment includes 65 RediClinic walk-in retail clinics, of which, 29 were located within Rite Aid retail stores in the Philadelphia and New Jersey markets.

Pharmacy Services Segment

Our Pharmacy Services segment provides a full range of pharmacy benefit services through EnvisionRxOptions. The Pharmacy Services segment provides both transparent and traditional PBM options through its EnvisionRxOptions and MedTrak PBMs, respectively. EnvisionRxOptions also offers fully integrated mail-order and specialty pharmacy services through EnvisionPharmacies; an innovative claims adjudication software platform in Laker Software; and a national Medicare Part D prescription drug plan through EIC’s EnvisionRx Plus product offering. The segment’s clients are primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans, Medicare plans, other sponsors of health benefit plans and individuals throughout the United States.

Restructuring

In March 2019, the Board of Directors implemented a reorganization of our executive management team to further streamline our business. In addition, we announced a restructuring plan that will reduce managerial layers and consolidate roles across the organization, resulting in the elimination of approximately 400 full-time positions located at our headquarters and across the field organization. Approximately two-thirds of the reductions took place at the time of the announcement and the balance will occur by the end of fiscal 2020.

In April 2019, we implemented our Path to the Future transformation initiative, which focuses primarily on opportunities to drive further growth and operating efficiency, including i) building solutions to work with regional health plans to improve patient health outcomes, ii) optimizing SKU's in our front-end offering to free up working capital and improve front-end profitability and the customer experience, iii) an assessment of our pricing and promotional strategy and, iv) a continued review of our cost structure, which includes opportunities to use technology and vendor partners to help reduce costs.

As a result of the restructuring that we announced in March, we expect to achieve annual cost savings of approximately $55.0 million, of which approximately $42.0 million is expected to be realized during the fiscal year ended February 29, 2020. These savings offset the reduction in TSA fees that we experienced in Fiscal 2020. We have

Table of Contents

also incurred restructuring costs to support our Path to the Future initiatives, which we expect to provide future growth and expense efficiency benefits. We anticipate our total fiscal 2020 restructuring-related costs to be approximately $90.0 million and expect to realize the full benefit of this investment over the next two years.

Asset Sale to WBA

On September 18, 2017, we entered into the Amended and Restated Asset Purchase Agreement with WBA and Buyer, which amended and restated in its entirety the previously disclosed Original Asset Purchase Agreement. Pursuant to the terms and subject to the conditions set forth in the Amended and Restated Asset Purchase Agreement, Buyer agreed to purchase from Rite Aid 1,932 Acquired Stores, three distribution centers, related inventory and other specified assets and liabilities related thereto for a purchase price of approximately $4.375 billion, on a cash-free, debt-free basis, in the Sale.

We announced on September 19, 2017 that the waiting period under the HSR Act expired with respect to the Sale. We completed the store transfer process in March of 2018, which resulted in the transfer of all 1,932 stores and related assets to WBA and received cash proceeds of $4.157 billion. On September 13, 2018, we completed the sale of one of our distribution centers and related assets to WBA for proceeds of $61.2 million. The transfer of the two remaining distribution centers and related assets remains subject to minimal customary closing conditions applicable only to the distribution centers being transferred at such distribution center closings, as specified in the Amended and Restated Asset Purchase Agreement. We will receive additional proceeds of $157.0 million upon completion of the sale of the remaining distribution centers and related assets.

The parties to the Amended and Restated Asset Purchase Agreement have each made customary representations and warranties. We have agreed to various covenants and agreements, including, among others, our agreement to conduct our business at the distribution centers being sold to WBA in the ordinary course during the period between the execution of the Amended and Restated Asset Purchase Agreement and the distribution center closing. We have also agreed to provide transition services to Buyer for up to three years after the initial closing of the Sale. Under the terms of the TSA, we provide various services on behalf of WBA, including but not limited to the purchase and distribution of inventory and virtually all selling, general and administrative activities. The term of the TSA has been extended to October 17, 2020. In connection with these services, we purchase the related inventory and incur cash payments for the selling, general and administrative activities, which, we bill on a cash neutral basis to WBA in accordance with terms as outlined in the TSA. Total billings for these items during the thirteen and twenty-six week periods ended August 31, 2019 were $0.9 billion and $2.1 billion, respectively, of which $196.0 million is included in Accounts receivable, net. Total billings for these items during the thirteen and twenty-six week periods ended September 1, 2018 were $1.8 billion and $3.9 billion, respectively, of which $385.9 million is included in Accounts receivable, net. We recorded WBA TSA fees of $11.3 million and $25.5 million during the thirteen and twenty-six week periods ended August 31, 2019, respectively, which are reflected as a reduction to selling, general and administrative expenses. We recorded WBA TSA fees of $23.2 million and $46.9 million during the thirteen and twenty-six week periods ended September 1, 2018, respectively, which are reflected as a reduction to selling, general and administrative expenses.

Based on its magnitude and because we exited certain markets, the Sale represented a significant strategic shift that has a material effect on our operations and financial results. Accordingly, we have applied discontinued operations treatment for the Sale as required by GAAP.

Overview of Financial Results from Continuing Operations

Our net loss from continuing operations for the thirteen week period ended August 31, 2019 was $78.7 million or $1.48 per basic and diluted share compared to a net loss of $352.3 million or $6.67 per basic and diluted share for the thirteen week period ended September 1, 2018. Our net loss from continuing operations for the twenty-six week period ended August 31, 2019 was $178.0 million or $3.35 per basic and diluted share compared to a net loss of $394.1 million or $7.47 per basic and diluted share for the twenty-six week period ended September 1, 2018. The improvement in our operating results for the thirteen and twenty-six week periods ended August 31, 2019 was due primarily to goodwill and intangible asset impairment charges recognized in the prior year of $375.2 million, lower depreciation and amortization

Table of Contents

and lease termination and impairment charges, partially offset by restructuring-related costs incurred in connection with our Path to the Future initiative in the current year, a decrease in Adjusted EBITDA and higher income tax expense.

Our Adjusted EBITDA from continuing operations for the thirteen and twenty-six week periods ended August 31, 2019 was $134.2 million or 2.5 percent of revenues and $244.5 million or 2.3 percent of revenues, respectively, compared to $148.6 million or 2.7 percent of revenues and $286.6 million or 2.7 percent of revenues for the thirteen and twenty-six week periods ended September 1, 2018, respectively. The decrease in Adjusted EBITDA for the thirteen week period ended August 31, 2019 was due primarily to a decrease of $10.9 million in the Retail Pharmacy segment. The decrease in the Retail Pharmacy segment Adjusted EBITDA was due primarily to lower front-end gross profit resulting primarily from lower front-end sales and a reduction in WBA TSA fee income due to fewer stores being serviced under the TSA. These items were partially offset by lower salaries and benefit expense related to our recent corporate restructuring and strong labor and expense control at the stores. Adjusted EBITDA decreased by $3.4 million in the Pharmacy Services segment. Pharmacy Services segment Adjusted EBITDA benefited from improvements in pharmacy network performance, however these improvements were offset by increases in SG&A to support current year and future growth.

The decrease in Adjusted EBITDA for the twenty-six week period ended August 31, 2019 was due primarily to a decrease of $31.1 million in the Retail Pharmacy segment. The decrease in the Retail Pharmacy segment Adjusted EBITDA was due primarily to a reduction in gross profit, partially offset by decreases in SG&A. The reduction in gross profit was due to reimbursement rate pressure and a reduction in front-end sales. Retail Pharmacy segment SG&A improvement was driven by strong labor and expense control at the stores and labor savings and expense management relating to the recent corporate restructuring. Adjusted EBITDA decreased by $11.0 million in the Pharmacy Services segment. The decline in the Pharmacy Services segment Adjusted EBITDA was driven by margin compression in its commercial business and other operating investments to support current year and future growth. Please see the sections entitled “Segment Analysis” and “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” below for additional details.

Consolidated Results of Operations-Continuing Operations

Revenues and Other Operating Data


	Thirteen Week Period Ended						Twenty-Six Week Period Ended
	August 31,			September 1,			August 31,			September 1,
	2019			2018			2019			2018
	(dollars in thousands except per share amounts)
Revenues(a)	$	5,366,264		$	5,421,362		$	10,738,853		$	10,809,852
Revenue (decline) growth		(1.0)	%		1.4	%		(0.7)	%		0.3	%
Net loss	$	(78,705)		$	(352,348)		$	(178,044)		$	(394,075)
Net loss per diluted share	$	(1.48)		$	(6.67)		$	(3.35)		$	(7.47)
Adjusted EBITDA(b)	$	134,190		$	148,581		$	244,537		$	286,573
Adjusted Net Income (Loss)(b)	$	6,288		$	(7,877)		$	(1,231)		$	(6,507)
Adjusted Net Income (Loss) per Diluted Share(b)	$	0.12		$	(0.15)		$	(0.02)		$	(0.12)

(a)

Revenues for the thirteen and twenty-six week periods ended August 31, 2019 exclude $60,909 and $119,420, respectively, of inter-segment activity that is eliminated in consolidation. Revenues for the thirteen and twenty-six week periods ended September 1, 2018 exclude $51,961 and $103,998, respectively, of inter-segment activity that is eliminated in consolidation.

(b)	See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.

Table of Contents

Revenues

Revenues decreased 1.0% and 0.7% for the thirteen and twenty-six weeks ended August 31, 2019, respectively, compared to an increase of 1.4% and 0.3% for the thirteen and twenty-six weeks ended September 1, 2018. Revenues for the thirteen week period ended August 31, 2019 were negatively impacted by a $63.4 million decrease in Retail Pharmacy segment revenues, partially offset by a $17.3 million increase in Pharmacy Services segment revenues. Revenues for the twenty-six week period ended August 31, 2019 were negatively impacted by a $96.4 million decrease in Retail Pharmacy segment revenues, partially offset by a $40.8 million increase in Pharmacy Services segment revenues. Same store sales trends for the thirteen week periods ended August 31, 2019 and September 1, 2018 are described in the “Segment Analysis” section below.

Please see the section entitled “Segment Analysis” below for additional details regarding revenues.

Costs and Expenses


	Thirteen Week Period Ended						Twenty-Six Week Period Ended
	August 31,			September 1,			August 31,			September 1,
	2019			2018			2019			2018
	(dollars in thousands)
Cost of revenues(a)	$	4,221,825		$	4,260,211		$	8,467,691		$	8,479,952
Gross profit		1,144,439			1,161,151			2,271,162			2,329,900
Gross margin		21.3	%		21.4	%		21.1	%		21.6	%
Selling, general and administrative expenses	$	1,135,530		$	1,153,991		$	2,298,182		$	2,306,618
Selling, general and administrative expenses as a percentage of revenues		21.2	%		21.3	%		21.4	%		21.3	%
Lease termination and impairment charges		1,471			39,609			1,949			49,468
Goodwill and intangible asset impairment charges		—			375,190			—			375,190
Interest expense		60,102			56,233			118,372			119,025
Gain on sale of assets, net		(1,587)			(4,965)			(4,299)			(10,824)

(a)

Cost of revenues for the thirteen and twenty-six week periods ended August 31, 2019 exclude $60,909 and $119,420, respectively, of inter-segment activity that is eliminated in consolidation. Cost of revenues for the thirteen and twenty-six week periods ended September 1, 2018 exclude $51,961 and $103,998, respectively, of inter-segment activity that is eliminated in consolidation.

Gross Profit and Cost of Revenues

Gross profit decreased by $16.7 million for the thirteen week period ended August 31, 2019 compared to the thirteen week period ended September 1, 2018. Gross profit decreased by $58.7 million for the twenty-six week period ended August 31, 2019 compared to the twenty-six week period ended September 1, 2018. Gross profit for the thirteen week period ended August 31, 2019 includes a decrease of $19.2 million in our Retail Pharmacy segment, partially offset by an increase of $2.5 million in our Pharmacy Services segment. Gross profit for the twenty-six week period ended August 31, 2019 includes a decrease of $58.2 million in our Retail Pharmacy segment and a decrease of $0.6 million in our Pharmacy Services segment. Gross margin was 21.3% for the thirteen week period ended August 31, 2019 compared to 21.4% for the thirteen week period ended September 1, 2018. The decline in gross margin was due primarily to a decline in pharmacy gross margin, partially offset by an increase in front-end gross margin due to lower markdown activity in the Retail Pharmacy segment. Gross margin was 21.1% for the twenty-six week period ended August 31, 2019 compared to 21.6% for the twenty-six week period ended September 1, 2018. The decline in gross margin was due primarily to a decline in pharmacy gross margin, partially offset by an increase in front-end gross margin due to lower markdown activity in the Retail Pharmacy segment. Please see the section entitled “Segment Analysis” for a more detailed description of gross profit and gross margin results by segment.

Table of Contents

Selling, General and Administrative Expenses

SG&A decreased by $18.5 million and $8.4 million for the thirteen and twenty-six week periods ended August 31, 2019, respectively, compared to the thirteen and twenty-six week periods ended September 1, 2018. The decrease in SG&A for the thirteen week period ended August 31, 2019 includes a decrease of $24.1 million relating to our Retail Pharmacy segment, partially offset by an increase of $5.6 million relating to our Pharmacy Services segment. The decrease in SG&A for the twenty-six week period ended August 31, 2019 includes a decrease of $17.2 million related to our Retail Pharmacy segment, partially offset by an increase of $8.8 million relating to our Pharmacy Services segment. Please see the section entitled “Segment Analysis” below for additional details regarding SG&A.

Lease Termination and Impairment Charges

Lease termination and impairment charges consist of amounts as follows:


	Thirteen Week				Twenty-Six Week
	Period Ended				Period Ended
	August 31,			September 1,	August 31,		September 1,
	2019		2018		2019		2018
Impairment charges	$	1,289	$	33,562	$	1,412	$	33,845
Lease termination charges		—		6,047		—		15,623
Facility exit charges		182		—		537		—
	$	1,471	$	39,609	$	1,949	$	49,468

Effective March 3, 2019, the Company adopted the Lease Standard. See the Recently Adopted Accounting Pronouncements section of Note 1 to the unaudited condensed consolidated financial statements for a detailed discussion of the adoption of this new lease standard.

Please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations—Lease Termination and Impairment Charges” included in our Fiscal 2019 10-K for a detailed description of our impairment and lease termination methodology for fiscal 2019.

Interest Expense

Interest expense was $60.1 million and $118.4 million for the thirteen and twenty-six week periods ended August 31, 2019, respectively, compared to $56.2 million and $119.0 million for the thirteen and twenty-six week periods ended September 1, 2018, respectively. Interest expense was higher for the thirteen week period ended August 31, 2019 due to higher revolver borrowings, partially offset by lower average interest rates. The weighted average interest rate on our indebtedness for the twenty-six week periods ended August 31, 2019 and September 1, 2018 was 5.4% and 6.2%, respectively.

Income Taxes

We recorded an income tax expense from continuing operations of $27.6 million and an income tax benefit from continuing operations of $106.6 million for the thirteen week periods ended August 31, 2019 and September 1, 2018, respectively. We recorded an income tax expense from continuing operations of $35.0 million and an income tax benefit from continuing operations of $116.1 million for the twenty-six week periods ended August 31, 2019 and September 1, 2018, respectively. The effective tax rate for the thirteen week periods ended August 31, 2019 and September 1, 2018 was (54.1)% and 23.2%, respectively. The effective tax rate for the twenty-six week periods ended August 31, 2019 and September 1, 2018 was (24.5)% and 22.8%, respectively. The effective tax rate for the thirteen and twenty-six week periods ended August 31, 2019 was net of an adjustment of (78.4)% and (50.2)%, respectively, to increase the valuation allowance against deferred tax assets created this period as well as for certain existing state deferred taxes whose realization is now uncertain due to a restructuring of our legal entities. The effective tax rate for the thirteen and twenty-six week periods ended September 1, 2018 included an adjustment of (4.2)% and (3.9)% to increase the valuation allowance related to certain state deferred taxes.

Table of Contents

We recognize tax liabilities in accordance with the guidance for uncertain tax positions and management adjusts these liabilities with changes in judgment as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the tax liabilities.

We believe that it is reasonably possible that a decrease of up to $7.4 million in unrecognized tax benefits related to state exposures may be necessary in the next twelve months however management does not expect the change to have a significant impact on the results of operations or the financial position of the Company.

We regularly evaluate valuation allowances established for deferred tax assets for which future realization is uncertain. We will continue to monitor all available evidence related to the net deferred tax assets that may change the most recent assessment, including events that have occurred or are anticipated to occur. We continue to maintain a valuation allowance against net deferred tax assets of $1,088.0 million and $1,091.4 million, which relates to federal and state deferred tax assets that may not be realized based on our future projections of taxable income at August 31, 2019 and March 2, 2019, respectively.

Segment Analysis

We evaluate the Retail Pharmacy and Pharmacy Services segments’ performance based on revenue, gross profit, and Adjusted EBITDA. The following is a reconciliation of our segments to the condensed consolidated financial statements:


	Retail		Pharmacy		Intersegment
	Pharmacy		Services		Eliminations(1)		Consolidated
Thirteen Week Period Ended
August 31, 2019:
Revenues	$	3,848,104	$	1,579,069	$	(60,909)	$	5,366,264
Gross Profit		1,032,444		111,995		—		1,144,439
Adjusted EBITDA(*)		92,673		41,517		—		134,190
September 1, 2018:
Revenues	$	3,911,512	$	1,561,811	$	(51,961)	$	5,421,362
Gross Profit		1,051,637		109,514		—		1,161,151
Adjusted EBITDA(*)		103,618		44,963		—		148,581
Twenty-Six Week Period Ended
August 31, 2019:
Revenues	$	7,712,912	$	3,145,361	$	(119,420)	$	10,738,853
Gross Profit		2,062,939		208,223		—		2,271,162
Adjusted EBITDA(*)		176,681		67,856		—		244,537
September 1, 2018:
Revenues	$	7,809,277	$	3,104,573	$	(103,998)	$	10,809,852
Gross Profit		2,121,094		208,806		—		2,329,900
Adjusted EBITDA(*)		207,747		78,826		—		286,573

(1)

(*) See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.

Table of Contents

Retail Pharmacy Segment Results of Operations

Revenues and Other Operating Data


	Thirteen Week Period Ended						Twenty-Six Week Period Ended
	August 31,			September 1,			August 31,			September 1,
	2019			2018			2019			2018
	(dollars in thousands)
Revenues	$	3,848,104		$	3,911,512		$	7,712,912		$	7,809,277
Revenue (decline) growth		(1.6)	%		0.2	%		(1.2)	%		(0.8)	%
Same store sales growth		0.4	%		1.0	%		0.9	%		0.1	%
Pharmacy sales (decline) growth		(0.5)	%		0.9	%		—	%		(0.2)	%
Same store prescription count growth (decline), adjusted to 30-day equivalents		2.7	%		1.1	%		3.2	%		(0.2)	%
Same store pharmacy sales growth		1.5	%		1.6	%		1.9	%		0.7	%
Pharmacy sales as a % of total retail sales		67.2	%		66.4	%		67.1	%		66.4	%
Front-end sales decline		(3.8)	%		(0.9)	%		(3.1)	%		(1.9)	%
Same store front-end sales decline		(1.8)	%		(0.1)	%		(1.1)	%		(1.0)	%
Front-end sales as a % of total retail sales		32.8	%		33.6	%		32.9	%		33.6	%
Adjusted EBITDA(*)	$	92,673		$	103,618		$	176,681		$	207,747
Store data:
Total stores (beginning of period)		2,466			2,533			2,469			2,550
New stores		—			1			1			1
Store acquisitions		—			—			—			—
Closed stores		(2)			(8)			(6)			(25)
Total stores (end of period)		2,464			2,526			2,464			2,526
Relocated stores		1			—			1			—
Remodeled and expanded stores		24			33			51			82

(*) See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.

Revenues

Revenues decreased 1.6% for the thirteen weeks ended August 31, 2019 compared to an increase of 0.2% for the thirteen weeks ended September 1, 2018. The decrease in revenues for the thirteen week period ended August 31, 2019 was primarily a result of store closings, partially offset by an increase in same store sales.

Pharmacy same store sales increased by 1.5% for the thirteen week period ended August 31, 2019 compared to an increase of 1.6% in the thirteen week period ended September 1, 2018. The increase in the current period is due to the 2.7% 30-day equivalent increase in same store prescription count, partially offset by continued reimbursement rate pressure.

Front-end same store sales decreased 1.8% during the thirteen week period ended August 31, 2019 compared to a decrease of 0.1% during the thirteen week period ended September 1, 2018. Front-end same store sales, excluding cigarettes and tobacco products, decreased 0.6% during the thirteen week period ended August 31, 2019.

Revenues decreased 1.2% for the twenty-six weeks ended August 31, 2019 compared to a decrease of 0.8% for the twenty-six weeks ended September 1, 2018. The decrease in revenues for the twenty-six week period ended August 31, 2019 was primarily a result of store closings, partially offset by an increase in same store sales.

Pharmacy same store sales increased by 1.9% for the twenty-six week period ended August 31, 2019 compared to an increase of 0.7% in the twenty-six week period ended September 1, 2018. The increase in the current period is due to the 3.2% 30-day equivalent increase in same store prescription count, partially offset by continued reimbursement rate pressure.

Table of Contents

Front-end same store sales decreased 1.1% during the twenty-six week period ended August 31, 2019 compared to a decrease of 1.0% during the twenty-six week period ended September 1, 2018. Front-end same store sales, excluding cigarettes and tobacco products, decreased 0.1% during the twenty-six week period ended August 31, 2019.

We include in same store sales all stores that have been open at least one year. Relocation stores are not included in same store sales until one year has lapsed.

Costs and Expenses


	Thirteen Week Period Ended						Twenty-Six Week Period Ended
	August 31,			September 1,			August 31,			September 1,
	2019			2018			2019			2018
	(dollars in thousands)
Cost of revenues	$	2,815,660		$	2,859,875		$	5,649,973		$	5,688,183
Gross profit		1,032,444			1,051,637			2,062,939			2,121,094
Gross margin		26.8	%		26.9	%		26.7	%		27.2	%
FIFO gross profit(*)		1,039,948			1,054,995			2,077,932			2,134,418
FIFO gross margin(*)		27.0	%		27.0	%		26.9	%		27.3	%
Selling, general and administrative expenses	$	1,044,818		$	1,068,944			2,116,143			2,133,331
Selling, general and administrative expenses as a percentage of revenues		27.2	%		27.3	%		27.4	%		27.3	%

(*) See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.

Gross Profit and Cost of Revenues

Gross profit decreased $19.2 million for the thirteen week period ended August 31, 2019 compared to the thirteen week period ended September 1, 2018, driven by a decline in front-end gross profit and an increase in LIFO charges. Front-end gross profit was worse than the prior year’s second quarter due to a decline in front-end sales. Pharmacy gross profit was flat as reimbursement rate declines were offset by generic purchasing efficiencies and the increase in same store prescription count.

Gross profit decreased $58.2 million for the twenty-six week period ended August 31, 2019 compared to the twenty-six week period ended September 1, 2018. Pharmacy gross profit was negatively impacted by reimbursement rate declines that we were not able to offset with both the generic purchasing efficiencies and the increase in same store prescription count. A portion of the decline in reimbursement rates was caused by adjusting our estimate for retroactive rate adjustments expected from a state Medicaid agency. Front-end gross profit was worse than the prior year due to a decline in front-end sales.

Gross margin was 26.8% of sales for the thirteen week period ended August 31, 2019 which was flat compared to 26.9% of sales for the thirteen week period ended September 1, 2018.

Gross margin was 26.7% of sales for the twenty-six week period ended August 31, 2019 compared to 27.2% of sales for the twenty-six week period ended September 1, 2018. The reduction in gross margin for the twenty-six week period was due primarily to reimbursement rate declines that we were not able to offset with generic purchasing efficiencies, partially offset by an improvement in front-end gross profit resulting from lower markdowns.

We use the last-in, first-out (“LIFO”) method of inventory valuation, which is estimated on a quarterly basis and is finalized at year end when inflation rates and inventory levels are final. Therefore, LIFO costs for interim period financial statements are estimated. LIFO charges were $7.5 million and $15.0 million for the thirteen and twenty-six week periods ended August 31, 2019, respectively, compared to $3.4 million and $13.3 million for the thirteen and twenty-six week periods ended September 1, 2018, respectively.

Table of Contents

Selling, General and Administrative Expenses

SG&A expenses decreased $24.1 million for the thirteen week period ended August 31, 2019 due primarily to strong labor and expense control at the stores, labor savings and expense management relating to the recent corporate restructuring, a prior year legal settlement and higher professional fees incurred in the prior year relating to the WBA and Albertsons transactions, partially offset by restructuring-related expenses incurred in connection with our Path to the Future transformation initiative and a reduction in WBA TSA fees due to servicing fewer stores. SG&A expenses as a percentage of revenues for the thirteen week period ended August 31, 2019 was flat compared to the thirteen week period ended September 1, 2018 as the decrease in SG&A expenses as noted above was offset by a loss of revenue leverage, as revenues declined.

SG&A expenses decreased $17.2 million for the twenty-six week period ended August 31, 2019 due to strong labor and expense control at the stores, labor savings and expense management relating to the recent corporate restructuring, a prior year legal settlement and higher professional fees incurred in the prior year relating to the WBA and Albertsons transactions, partially offset by restructuring-related expenses incurred in connection with our Path to the Future transformation initiative and a reduction in WBA TSA fees due to servicing fewer stores. SG&A expenses as a percentage of revenues for the twenty-six week period ended August 31, 2019 was flat compared to the twenty-six week period ended September 1, 2018 as the decrease in SG&A expenses as noted above was offset by a loss of revenue leverage, as revenues declined.

Pharmacy Services Segment Results of Operations

Revenues and Other Operating Data


	Thirteen Week Period Ended						Twenty-Six Week Period Ended
	August 31,			September 1,			August 31,			September 1,
	2019			2018			2019			2018
	(dollars in thousands)
Revenues	$	1,579,069		$	1,561,811		$	3,145,361		$	3,104,573
Revenue growth		1.1	%		4.6	%		1.3	%		3.3	%
Adjusted EBITDA(*)	$	41,517		$	44,963		$	67,856		$	78,826

(*) See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.

Revenues

Pharmacy Services segment revenues for the thirteen week period ended August 31, 2019 were $1,579.1 million as compared to revenues of $1,561.8 million for the thirteen week period ended September 1, 2018. Pharmacy Services segment revenues for the twenty-six week period ended August 31, 2019 were $3,145.4 million as compared to revenues of $3,104.6 million for the twenty-six week period ended September 1, 2018. The increase in revenues for the segment is primarily due to an increase in Medicare Part D Membership revenues, partially offset by client losses in our commercial business.

Table of Contents

Costs and Expenses


	Thirteen Week Period Ended						Twenty-Six Week Period Ended
	August 31,			September 1,			August 31,			September 1,
	2019			2018			2019			2018
	(dollars in thousands)
Cost of revenues	$	1,467,074		$	1,452,297		$	2,937,138		$	2,895,767
Gross profit		111,995			109,514			208,223			208,806
Gross margin		7.1	%		7.0	%		6.6	%		6.7	%
Selling, general and administrative expenses	$	90,712		$	85,047			182,039			173,287
Selling, general and administrative expenses as a percentage of revenues		5.7	%		5.4	%		5.8	%		5.6	%

Gross Profit and Cost of Revenues

Gross profit for the thirteen week period ended August 31, 2019 was $112.0 million as compared to gross profit of $109.5 million for the thirteen week period ended September 1, 2018. Gross profit for the twenty-six week period ended August 31, 2019 was $208.2 million as compared to gross profit of $208.8 million for the twenty-six week period ended September 1, 2018. The increase in the thirteen week gross profit for the segment is primarily due to improved pharmacy network management. Gross profit for the twenty-six week period was flat to the prior year.

Gross margin was 7.1% of sales for the thirteen week period ended August 31, 2019 compared to 7.0% of sales for the thirteen week period ended September 1, 2018. Gross margin was 6.6% of sales for the twenty-six week period ended August 31, 2019 compared to 6.7% of sales for the twenty-six week period ended September 1, 2018.

Selling, General and Administrative Expenses

Pharmacy Services segment selling, general and administrative expenses for the thirteen week period ended August 31, 2019 was $90.7 million as compared to $85.0 million for the thirteen week period ended September 1, 2018. Pharmacy Services segment selling, general and administrative expenses for the twenty-six week period ended August 31, 2019 was $182.0 million as compared to $173.3 million for the twenty-six week period ended September 1, 2018. Selling, general and administrative expenses as a percentage of Pharmacy Services segment revenue was 5.7% and 5.4% for the thirteen week periods ended August 31, 2019 and September 1, 2018, respectively. Selling, general and administrative expenses as a percentage of Pharmacy Services segment revenue was 5.8% and 5.6% for the twenty-six week periods ended August 31, 2019 and September 1, 2018, respectively. The increase in the thirteen and twenty-six week periods selling, general and administrative expenses is primarily the result of strategic investments to support current year and future growth.

Liquidity and Capital Resources

General

We have two primary sources of liquidity: (i) cash provided by operating activities and (ii) borrowings under our New Facilities. Our principal uses of cash are to provide working capital for operations, to service our obligations to pay interest and principal on debt and to fund capital expenditures. Total liquidity as of August 31, 2019 was $1,400.9 million, which consisted of revolver borrowing capacity of $1,366.8 million and invested cash of $34.1 million.

Credit Facilities

On December 20, 2018, we entered into a new senior secured credit agreement, consisting of a new $2.7 billion senior secured asset-based revolving credit facility (“Senior Secured Revolving Credit Facility”) and a new $450.0 million “first-in, last out” senior secured term loan facility (“Senior Secured Term Loan”) (collectively the “New Facilities”). Proceeds from the New Facilities were used to refinance our prior $2.7 billion Amended and Restated Senior Secured Credit Facility due January 2020 (the “Old Facility”, the New Facilities and the Old Facility are collectively referred to herein as the “Facilities”). The New Facilities extend our debt maturity profile and provide additional

Table of Contents

liquidity. The New Facilities mature in December 2023, subject to an earlier maturity on December 31, 2022 if we have not repaid or refinanced our existing 6.125% Senior Notes due 2023 prior to such date. It is our intention to repay or refinance our existing 6.125% Senior Notes due 2023 prior to the early maturity becoming effective. Our Senior Secured Revolving Credit Facility will bear interest at a rate of LIBOR plus 125 to 175 basis points (or an alternate base rate plus 25 to 75 basis points), depending on availability under the revolving facility. Our new Senior Secured Term Loan will bear interest at a rate of LIBOR plus 300 basis points (or an alternate base rate plus 200 basis points).

Our ability to borrow under our New Facilities is based upon a specified borrowing base consisting of accounts receivable, inventory and prescription files. At August 31, 2019, we had $1,700.0 million of borrowings outstanding under the New Facilities and had letters of credit outstanding against the New Facilities of $83.2 million, which resulted in additional borrowing capacity of $1,366.8 million. If at any time the total credit exposure outstanding under our New Facilities and the principal amount of our other senior obligations exceed the borrowing base, we are required to make certain other mandatory prepayments to eliminate such shortfall.

The New Facilities restrict us and all of our subsidiaries that guarantee our obligations under the New Facilities and unsecured guaranteed notes (the “Subsidiary Guarantors”) from accumulating cash on hand in excess of $200.0 million at any time when revolving loans are outstanding (not including cash located in our store and lockbox deposit accounts and cash necessary to cover our current liabilities). The New Facilities also state that if at any time (other than following the exercise of remedies or acceleration of any senior obligations or second priority debt and receipt of a triggering notice by the senior collateral agent from a representative of the senior obligations or the second priority debt) either (i) an event of default exists under our New Facilities or (ii) the sum of revolver availability under our Senior Secured Revolving Credit Facility and certain amounts held on deposit with the senior collateral agent in a concentration account is less than $275.0 million for three consecutive business days or less than or equal to $200.0 million on any day (a “cash sweep period”), the funds in our deposit accounts will be swept to a concentration account with the senior collateral agent and will be applied first to repay outstanding revolving loans under the New Facilities, and then held as collateral for the senior obligations until such cash sweep period is rescinded pursuant to the terms of our New Facilities.

The New Facilities allow us to have outstanding, at any time, up to $1.5 billion in secured second priority debt, split-priority term loan debt, unsecured debt and disqualified preferred stock in addition to borrowings under the New Facilities and existing indebtedness, provided that not in excess of $750.0 million of such secured second priority debt, split-priority term loan debt, unsecured debt and disqualified preferred stock shall mature or require scheduled payments of principal prior to 90 days after the latest of (i) the fifth anniversary of the effectiveness of the New Facilities and (ii) the latest maturity date of any Term Loan or Other Revolving Commitment (each as defined in the New Facilities). Subject to the limitations described in clauses (i) and (ii) of the immediately preceding sentence, the New Facilities additionally allow us to issue or incur an unlimited amount of unsecured debt and disqualified preferred stock so long as a Financial Covenant Effectiveness Period (as defined in the New Facilities) is not in effect; provided, however, that certain of our other outstanding indebtedness limits the amount of unsecured debt that can be incurred if certain interest coverage levels are not met at the time of incurrence or other exemptions are not available. The New Facilities also contain certain restrictions on the amount of secured first priority debt we are able to incur. The New Facilities also allow for the voluntary repurchase of any debt or other convertible debt, so long as the New Facilities are not in default and we maintain availability under our revolver of more than $365.0 million.

The New Facilities have a financial covenant that requires us to maintain a minimum fixed charge coverage ratio of 1.00 to 1.00 (i) on any date on which availability under the revolver is less than $200.0 million or (ii) on the third consecutive business day on which availability under the revolver is less than $250.0 million and, in each case, ending on and excluding the first day thereafter, if any, which is the 30th consecutive calendar day on which availability under the revolver is equal to or greater than $250.0 million. As of August 31, 2019, we had availability under our New Facilities of $1,366.8 million, our fixed charge coverage ratio was greater than 1.00 to 1.00, and we were in compliance with the New Facilities’ financial covenant. The New Facilities also contain covenants which place restrictions on the incurrence of debt, the payments of dividends, sale of assets, mergers and acquisitions and the granting of liens.

The New Facilities provide for customary events of default including nonpayment, misrepresentation, breach of covenants and bankruptcy. It is also an event of default if we fail to make any required payment on debt having a principal amount in excess of $50.0 million or any event occurs that enables, or which with the giving of notice or the

Table of Contents

lapse of time would enable, the holder of such debt to accelerate the maturity or require the repayment repurchase, redemption or defeasance of such debt.

The indenture that governs our guaranteed unsecured notes contains restrictions on the amount of additional secured and unsecured debt that can be incurred by us. As of August 31, 2019, the amount of additional secured debt that could be incurred under the most restrictive covenant of the indenture was approximately $1.8 billion (which amount does not include the ability to enter into certain sale and leaseback transactions). Assuming a fully drawn revolver and the outstanding letters of credit, we could incur an additional $350.0 million in secured debt. The ability to issue additional unsecured debt under the indenture is generally governed by an interest coverage ratio test. As of August 31, 2019, we had the ability to issue additional unsecured debt under our other indentures.

Net Cash Provided by/Used in Operating, Investing and Financing Activities

Cash used in operating activities was $330.0 million and $300.9 million for the twenty-six week periods ended August 31, 2019 and September 1, 2018, respectively. Operating cash flow was negatively impacted by the increase in amounts due from CMS, seasonal inventory build, payments to fund the fiscal 2019 401(k) contribution and bonus payments, as well as the timing of working capital items.

Cash used in investing activities was $95.3 million and $94.8 million for the twenty-six week periods ended August 31, 2019 and September 1, 2018, respectively. Cash used for the purchase of property, plant, and equipment was consistent with the prior year. During the twenty-six week period ended August 31, 2019, we remodeled 51 stores and spent $15.7 million on file buys.

Cash flow provided by financing activities was $425.0 million compared to cash flow used in financing activities of $883.2 million for the twenty-six week periods ended August 31, 2019 and September 1, 2018, respectively. Cash provided by financing activities for the twenty-six weeks ended August 31, 2019 reflects net revolver borrowings and the change in our zero balance accounts due to the timing of payments.

Capital Expenditures

During the thirteen and twenty-six week periods ended August 31, 2019 and September 1, 2018 capital expenditures were as follows:


	Thirteen Week Period Ended				Twenty-Six Week Period Ended
	August 31,		September 1,		August 31,		September 1,
	2019		2018		2019		2018

New store construction, store relocation and store remodel projects	$	16,727	$	20,986	$	37,334	$	45,875
Technology enhancements, improvements to distribution centers and other corporate requirements		26,352		23,608		46,726		46,690
Purchase of prescription files from other retail pharmacies		7,498		6,864		15,708		20,519
Total capital expenditures	$	50,577	$	51,458	$	99,768	$	113,084

Future Liquidity

We are highly leveraged. Our high level of indebtedness could: (i) limit our ability to obtain additional financing; (ii) limit our flexibility in planning for, or reacting to, changes in our business and the industry; (iii) place us at a competitive disadvantage relative to our competitors with less debt; (iv) render us more vulnerable to general adverse economic and industry conditions; and (v) require us to dedicate a substantial portion of our cash flow to service our debt. Based upon our current levels of operations, we believe that cash flow from operations together with available borrowings under the revolver and other sources of liquidity will be adequate to meet our requirements for working capital, debt service and capital expenditures at least for the next twelve months. Based on our liquidity position, which we expect to remain strong throughout the 2020 fiscal year, we do not expect to be subject to the fixed charge covenant in our New Facilities in the next twelve months. We will continue to assess our liquidity position and potential sources of

Table of Contents

supplemental liquidity in light of our operating performance, and other relevant circumstances. From time to time, we may seek additional deleveraging or refinancing transactions, including entering into transactions to exchange debt for shares of common stock, issuance of equity (including preferred stock and convertible securities), repurchase or redemption of outstanding indebtedness, or seek to refinance our outstanding debt (including our Facilities) or may otherwise seek transactions to reduce interest expense and extend debt maturities, particularly following the Sale and implementation of our strategies following the termination of the Merger. Any of these transactions could impact our financial results. We may also use additional Sale proceeds for one or more of these purposes in accordance with our outstanding agreements.

Critical Accounting Policies and Estimates

For a description of the critical accounting policies that require the use of significant judgments and estimates by management, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations—Critical Accounting Policies and Estimates” included in our Fiscal 2019 10-K, which we filed with the SEC on April 25, 2019, and the First Quarter 2020 10-Q, which we filed on July 11, 2019.

Factors Affecting Our Future Prospects

For a discussion of risks related to our financial condition, operations and industry, refer to “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations” included in our Fiscal 2019 10-K.

Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures

In addition to net income (loss) determined in accordance with GAAP, we use certain non-GAAP measures, such as “Adjusted EBITDA”, in assessing our operating performance. We believe the non-GAAP measures serve as an appropriate measure in evaluating the performance of our business. We define Adjusted EBITDA as net income (loss) excluding the impact of income taxes, interest expense, depreciation and amortization, LIFO adjustments (which removes the entire impact of LIFO, and effectively reflects the results as if we were on a FIFO inventory basis), charges or credits for facility closing and impairment, goodwill and intangible asset impairment charges, inventory write-downs related to store closings, loss on debt retirements, the WBA merger termination fee, and other items (including stock-based compensation expense, merger and acquisition-related costs, a non-recurring litigation settlement (as further discussed below), severance, restructuring-related costs and costs related to facility closures and gain or loss on sale of assets). We reference this particular non-GAAP financial measure frequently in our decision-making because it provides supplemental information that facilitates internal comparisons to the historical periods and external comparisons to competitors. In addition, incentive compensation is primarily based on Adjusted EBITDA and we base certain of our forward-looking estimates on Adjusted EBITDA to facilitate quantification of planned business activities and enhance subsequent follow-up with comparisons of actual to planned Adjusted EBITDA.

Table of Contents

The following is a reconciliation of our net loss to Adjusted EBITDA for the thirteen and twenty-six week periods ended August 31, 2019 and September 1, 2018:


	Thirteen Week Period Ended				Twenty-Six Week Period Ended
	August 31,		September 1,		August 31,		September 1,
	2019		2018		2019		2018(a)
	(dollars in thousands)
Net loss from continuing operations	$	(78,705)	$	(352,348)	$	(178,044)	$	(394,075)
Interest expense		60,102		56,233		118,372		119,025
Income tax expense (benefit)		27,628		(106,559)		35,002		(116,056)
Depreciation and amortization		83,044		89,743		166,970		184,272
LIFO charge		7,504		3,358		14,993		13,324
Lease termination and impairment charges		1,471		39,609		1,949		49,468
Goodwill and intangible asset impairment charges		—		375,190		—		375,190
Loss on debt retirements, net		—		—		—		554
Merger and Acquisition‑related costs		514		19,031		3,599		26,219
Stock-based compensation expense		4,712		5,215		10,092		10,246
Restructuring-related costs		25,145		—		68,495		—
Inventory write-downs related to store closings		3,149		1,300		3,990		5,133
Litigation settlement		—		18,000		—		18,000
Gain loss on sale of assets, net		(1,587)		(4,965)		(4,299)		(10,824)
Other		1,213		4,774		3,418		6,097
Adjusted EBITDA from continuing operations	$	134,190	$	148,581	$	244,537	$	286,573

(a)

During fiscal 2019, we revised our definition of Adjusted EBITDA to no longer exclude the impact of revenue deferrals related to our customer loyalty program and further revised our disclosure by presenting certain amounts previously included within Other as separate reconciling items. Consequently, we revised Adjusted EBITDA for the thirteen and twenty-six week period ended September 1, 2018 to conform with the revised definition and present separate reconciling items previously included with Other.

The following is a reconciliation of our net income (loss) from continuing operations to Adjusted Net (Loss) Income and Adjusted Net (Loss) Income per Diluted Share for the thirteen and twenty-six week periods ended August 31, 2019 and September 1, 2018. Adjusted Net Income (Loss) is defined as net income (loss) excluding the impact of amortization expense, merger and acquisition-related costs, a non-recurring litigation settlement (as further discussed below), loss on debt retirements, LIFO adjustments (which removes the entire impact of LIFO, and effectively reflects the results as if we were on a FIFO inventory basis), goodwill and intangible asset impairment charges, restructuring-related costs and the WBA merger termination fee. We calculate Adjusted Net Income (Loss) per Diluted Share using our above-referenced definition of Adjusted Net Income (Loss). We believe Adjusted Net Income (Loss) and Adjusted

Table of Contents

Net Income (Loss) per Diluted Share are useful indicators of our operating performance over multiple periods. Adjusted Net Income (Loss) per Diluted Share is calculated using our above-referenced definition of Adjusted Net Income (Loss):


	Thirteen Week Period Ended				Twenty-Six Week Period Ended
	August 31,		September 1,		August 31,		September 1,
	2019		2018		2019		2018(b)
	(dollars in thousands)
Net loss	$	(78,705)	$	(352,348)	$	(178,044)	$	(394,075)
Add back - Income tax expense (benefit)		27,628		(106,559)		35,002		(116,056)
Loss before income taxes		(51,077)		(458,907)		(143,042)		(510,131)
Adjustments:
Amortization expense		26,596		32,500		54,256		67,900
LIFO charge		7,504		3,358		14,993		13,324
Goodwill and intangible asset impairment charges		—		375,190		—		375,190
Loss on debt retirements, net		—		—		—		554
Merger and Acquisition‑related costs		514		19,031		3,599		26,219
Restructuring-related costs		25,145		—		68,495		—
Litigation settlement		—		18,000		—		18,000
Adjusted income (loss) before income taxes		8,682		(10,828)		(1,699)		(8,944)
Adjusted income tax expense (benefit) (a)		2,394		(2,951)		(468)		(2,437)
Adjusted net income (loss)		6,288	$	(7,877)	$	(1,231)	$	(6,507)
Net loss per diluted share	$	(1.48)	$	(6.67)	$	(3.35)	$	(7.47)
Adjusted net income (loss) per diluted share	$	0.12	$	(0.15)	$	(0.02)	$	(0.12)

(a)	The fiscal year 2020 and 2019 annual effective tax rates, calculated using a federal rate plus a net state rate that excluded the impact of state NOL’s, state credits and valuation allowance, was used for the thirteen and twenty-six weeks ended August 31, 2019 and September 1, 2018, respectively.

(b)

During fiscal 2019, we revised our definition of Adjusted Net Loss and Adjusted Net Loss per Diluted Share to exclude the impact of all amortization expense rather than only the impact of amortization expense related to the EnvisionRx intangible assets. Consequently, we have updated the Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share for the thirteen and twenty-six week periods ended September 1, 2018 to be reflective of our modified definition.

In addition to Adjusted EBITDA, Adjusted Net (Loss) Income and Adjusted Net (Loss) Income per Diluted Share, we occasionally refer to several other Non-GAAP measures, on a less frequent basis, in order to describe certain components of our business and how we utilize them to describe our results. These measures include but are not limited to Adjusted EBITDA Gross Margin and Gross Profit (gross margin/gross profit excluding non-Adjusted EBITDA items), Adjusted EBITDA SG&A (SG&A expenses excluding non-Adjusted EBITDA items), FIFO Gross Margin and FIFO Gross Profit (gross margin/gross profit before LIFO charges), and Free Cash Flow (Adjusted EBITDA less cash paid for interest, rent on closed stores, capital expenditures, acquisition costs and the change in working capital).

We include these non-GAAP financial measures in our earnings announcements in order to provide transparency to our investors and enable investors to better compare our operating performance with the operating performance of our competitors including with those of our competitors having different capital structures. Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share or other non-GAAP measures should not be considered in isolation from, and are not intended to represent an alternative measure of, operating results or of cash flows from operating activities, as determined in accordance with GAAP. Our definition of these non-GAAP measures may not be comparable to similarly titled measurements reported by other companies.

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

Our future earnings, cash flow and fair values relevant to financial instruments are dependent upon prevalent market rates. Market risk is the risk of loss from adverse changes in market prices and interest rates. Our major market

Table of Contents

risk exposure is changing interest rates. Increases in interest rates would increase our interest expense. We enter into debt obligations to support capital expenditures, acquisitions, working capital needs and general corporate purposes. Our policy is to manage interest rates through the use of a combination of variable-rate credit facilities, fixed-rate long-term obligations and derivative transactions.

The table below provides information about our financial instruments that are sensitive to changes in interest rates. The table presents principal payments and the related weighted average interest rates by expected maturity dates as of August 31, 2019 and assumes that we have not repaid or refinanced our existing 6.125% Senior Notes due 2023 prior to December 31, 2022.


																						Fair Value at
	2020			2021			2022			2023			2024			Thereafter			Total			August 31, 2019
	(Dollars in thousands)
Long-term debt, including current portion, excluding financing lease obligations
Fixed Rate	$	—		$	—		$	—		$	—		$	1,753,490		$	423,000		$	2,176,490		$	1,626,965
Average Interest Rate		0.00	%		0.00	%		0.00	%		0.00	%		6.13	%		7.45	%		6.38	%
Variable Rate	$	—		$	—		$	—		$	—		$	1,700,000		$	—		$	1,700,000		$	1,700,000
Average Interest Rate		0.00	%		0.00	%		0.00	%		0.00	%		3.89	%		0.00	%		3.89	%

Our ability to satisfy interest payment obligations on our outstanding debt will depend largely on our future performance, which, in turn, is subject to prevailing economic conditions and to financial, business and other factors beyond our control. If we do not have sufficient cash flow to service our interest payment obligations on our outstanding indebtedness and if we cannot borrow or obtain equity financing to satisfy those obligations, our business and results of operations could be materially adversely affected. We cannot be assured that any replacement borrowing or equity financing could be successfully completed.

The interest rate on our variable rate borrowings, which include our revolving credit facility and our term loan facility, are based on LIBOR. If the market rates of interest for LIBOR changed by 100 basis points as of August 31, 2019, our annual interest expense would change by approximately $17.0 million. Our annual interest expense would change by approximately $12.8 million when considering the benefit of the Cap which became effective on March 21, 2019.

A change in interest rates does not have an impact upon our future earnings and cash flow for fixed-rate debt instruments. As fixed-rate debt matures, however, and if additional debt is acquired to fund the debt repayment, future earnings and cash flow may be affected by changes in interest rates. This effect would be realized in the periods subsequent to the periods when the debt matures. Increases in interest rates would also impact our ability to refinance existing maturities on favorable terms.

ITEM 4. Controls and Procedures

(a) Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, our disclosure controls and procedures are effective.

(b) Changes in Internal Control over Financial Reporting

There have not been any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. Legal Proceedings

The information in response to this item is incorporated herein by reference to Note 16, Commitments, Contingencies and Guarantees, of the Consolidated Condensed Financial Statements of this Quarterly Report.

ITEM 1A. Risk Factors

In addition to the information set forth in this Quarterly Report, you should carefully consider the factors discussed in Part I, Item 1A, “Risk Factors” in our Fiscal 2019 10-K, which could materially affect our business, financial condition or future results.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Repurchases of Equity Securities. The table below is a listing of repurchases of common stock during the second quarter of fiscal 2020.


	Total			Total Number of Shares	Maximum Number of
	Number of	Average		Purchased as Part of	Shares that may yet be
	Shares	Price Paid		Publicly Announced	Purchased under the
Fiscal period:	Repurchased	Per Share		Plans or Programs	Plans or Programs
June 2 to June 29, 2019	39	$	7.74	—	—
June 30 to July 27, 2019	33	$	7.79	—	—
July 28 to August 31, 2019	62	$	5.81	—	—

ITEM 3. Defaults Upon Senior Securities

Not applicable.

ITEM 4. Mine Safety Disclosures

Not applicable.

ITEM 5. Other Information

Not applicable.

ITEM 6. Exhibits

(a)

The following exhibits are filed as part of this report.


Exhibit Numbers	Description	Incorporation By Reference To
2.1	Amended and Restated Asset Purchase Agreement, dated September 18, 2017, among Rite Aid Corporation, Walgreens Boots Alliance, Inc. and Walgreen Co.**	Exhibit 2.1 to Form 8-K, filed on September 19, 2017
2.2	Agreement and Plan of Merger, dated February 18, 2018, among Rite Aid Corporation, Albertsons Companies, Inc., Ranch Acquisition II LLC and Ranch Acquisition Corp.**	Exhibit 2.1 to Form 8-K, filed on February 20, 2018
2.3	Termination Agreement, dated as of August 8, 2018, among Rite Aid Corporation, Albertsons Companies, Inc., Ranch Acquisition II LLC and Ranch Acquisition Corp.	Exhibit 2.1 to Form 8-K, filed on August 8, 2018
3.1	Amended and Restated Certificate of Incorporation	Exhibit 3.1 to Form 8-K, filed on April 18, 2019

Table of Contents


Exhibit Numbers	Description	Incorporation By Reference To
3.2	Amended and Restated By-Laws	Exhibit 3.1 to Form 8-K, filed on April 10, 2019
4.1	Indenture, dated as of August 1, 1993, between Rite Aid Corporation, as issuer, and Morgan Guaranty Trust Company of New York, as trustee, related to the Company’s 7.70% Notes due 2027	Exhibit 4A to Registration Statement on Form S-3, File No. 033-63794, filed on June 3, 1993
4.2	Supplemental Indenture, dated as of February 3, 2000, between Rite Aid Corporation and U.S. Bank Trust National Association (as successor trustee to Morgan Guaranty Trust Company of New York) to the Indenture dated as of August 1, 1993, between Rite Aid Corporation and Morgan Guaranty Trust Company of New York, relating to the Company’s 7.70% Notes due 2027	Exhibit 4.1 to Form 8-K filed on February 7, 2000
4.3	Indenture, dated as of December 21, 1998, between Rite Aid Corporation, as issuer, and Harris Trust and Savings Bank, as trustee, related to the Company’s 6.875% Notes due 2028	Exhibit 4.1 to Registration Statement on Form S-4, File No. 333-74751, filed on March 19, 1999
4.4	Supplemental Indenture, dated as of February 3, 2000, between Rite Aid Corporation and Harris Trust and Savings Bank to the Indenture, dated December 21, 1998, between Rite Aid Corporation and Harris Trust and Savings Bank, related to the Company’s 6.875% Notes due 2028	Exhibit 4.4 to Form 8-K, filed on February 7, 2000
4.5	Registration Rights Agreement, dated as of February 10, 2015, by and among Rite Aid Corporation, TPG VI Envision, L.P., TPG VI DE BDH, L.P. and Envision Rx Options Holdings Inc.	Exhibit 10.3 to Form 8-K, filed on February 13, 2015
4.6	Indenture, dated as of April 2, 2015, among Rite Aid Corporation, as issuer, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., related to the Company’s 6.125% Senior Notes due 2023	Exhibit 4.1 to Form 8-K, filed on April 2, 2015
4.8	Supplemental Indenture, dated as of August 23, 2018, among Rite Aid Corporation, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., to the Indenture, dated as of April 2, 2015, among Rite Aid Corporation, as issuer, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., related to the Company’s 6.125% Senior Notes due 2023	Exhibit 4.1 to Form 8-K filed on August 23, 2018
4.9	Supplemental Indenture, dated as of February 8, 2019, among Rite Aid Corporation, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., to the Indenture, dated as of April 2, 2015, among Rite Aid Corporation, as issuer, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., related to the Company’s 6.125% Senior Notes due 2023	Exhibit 4.9 to Form 10-K filed on April 25, 2019
10.1	2000 Omnibus Equity Plan	Included in Proxy Statement dated October 24, 2000
10.2	2001 Stock Option Plan	Exhibit 10.3 to Form 10-K, filed on May 21, 2001
10.3	2004 Omnibus Equity Plan	Exhibit 10.4 to Form 10-K, filed on April 29, 2005
10.4	2006 Omnibus Equity Plan	Exhibit 10 to Form 8-K, filed on January 22, 2007
10.5	2010 Omnibus Equity Plan	Exhibit 10.1 to Form 8-K, filed on June 25, 2010

Table of Contents


Exhibit Numbers	Description	Incorporation By Reference To
10.6	Amendment No. 1, dated September 21, 2010, to the 2010 Omnibus Equity Plan	Exhibit 10.7 to Form 10-Q, filed on October 7, 2010
10.7	Amendment No. 2, dated January 16, 2013, to the 2010 Omnibus Equity Plan	Exhibit 10.8 to Form 10-K, filed on April 23, 2013
10.8	2012 Omnibus Equity Plan	Exhibit 10.1 to Form 8-K, filed on June 25, 2012
10.9	Amendment No. 1, dated January 16, 2013, to the 2012 Omnibus Equity Plan	Exhibit 10.10 to Form 10-K, filed on April 23, 2013
10.10	2014 Omnibus Equity Plan	Exhibit 10.1 to Form 8-K, filed on June 23, 2014
10.11	Form of Award Agreement	Exhibit 10.2 to Form 8-K, filed on May 15, 2012
10.12	Supplemental Executive Retirement Plan	Exhibit 10.6 to Form 10-K, filed on April 28, 2010
10.13	Executive Incentive Plan for Officers of Rite Aid Corporation	Exhibit 10.1 to Form 8-K, filed on February 24, 2012
10.14	Amended and Restated Employment Agreement by and between Rite Aid Corporation and John T. Standley, dated as of January 21, 2010	Exhibit 10.7 to Form 10-K, filed on April 28, 2010
10.15	Employment Agreement by and between Rite Aid Corporation and Douglas E. Donley, dated as of August 1, 2000	Exhibit 10.1 to Form 10-Q, filed on December 22, 2005
10.16	Amendment No. 1 to Employment Agreement by and between Rite Aid Corporation and Douglas E. Donley, dated as of December 18, 2008	Exhibit 10.4 to Form 10-Q, filed on January 7, 2009
10.17	Employment Agreement, dated as of July 24, 2014, by and between Rite Aid Corporation and Darren W. Karst	Exhibit 10.2 to Form 10-Q, filed on October 2, 2014
10.18	Letter Agreement, dated October 26, 2015, to the Employment Agreement by and between Rite Aid Corporation and Darren W. Karst, dated as of July 24, 2014	Exhibit 10.1 to Form 8-K, filed on October 28, 2015
10.19	Employment Agreement by and between Rite Aid Corporation and Jocelyn Konrad dated as of August 18, 2015	Exhibit 10.1 to Form 10-Q, filed on January 6, 2016
10.20	Employment Agreement by and between Rite Aid Corporation and Bryan Everett dated as of June 22, 2015	Exhibit 10.2 to Form 10-Q, filed on January 6, 2016
10.21	Employment Agreement by and between Rite Aid Corporation and David Abelman dated as of August 3, 2015	Exhibit 10.3 to Form 10-Q, filed on January 6, 2016
10.22	Form of Retention Award Agreement	Exhibit 10.1 to Form 8-K, filed on January 7, 2016
10.23	Form of December 31, 2015 Retention Award Agreement	Exhibit 10.2 to Form 8-K, filed on January 7, 2016
10.24	Credit Agreement, dated as of December 20, 2018, among Rite Aid Corporation, the lenders from time to time party thereto and Bank of America, N.A., as administrative agent and collateral agent.	Exhibit 10.1 to Form 8-K, filed on December 20, 2018

Table of Contents


Exhibit Numbers	Description	Incorporation By Reference To
10.25	Amended and Restated Collateral Trust and Intercreditor Agreement, including the related definitions annex, dated as of June 5, 2009, among Rite Aid Corporation, each subsidiary named therein or which becomes a party thereto, Wilmington Trust Company, as collateral trustee, Citicorp North America, Inc., as senior collateral processing agent, The Bank of New York Trust Company, N.A., as trustee under the 2017 7.5% Note Indenture (as defined therein) and The Bank of New York Mellon Trust Company, N.A., as trustee under the 2016 10.375% Note Indenture (as defined therein), and each other Second Priority Representative and Senior Representative which becomes a party thereto	Exhibit 10.3 to Form 8-K, filed on June 11, 2009
10.26	Standstill Agreement, dated as of February 18, 2018, among Rite Aid Corporation, Albertsons Companies, Inc. and Cerberus Capital Management, L.P.	Exhibit 10.1 to Form 8-K, filed on February 20, 2018
10.27	Employment Agreement by and between RxOptions, LLC and its affiliates operating the EnvisionRXOptions business and Ben Bulkley dated February 15, 2019	Exhibit 10.27 to Form 10-K, filed on April 25, 2019
10.28	Separation Agreement by and between Rite Aid Corporation and John T. Standley, dated as of March 12, 2019	Exhibit 10.28 to Form 10-Q, filed on July 11, 2019
10.29	Separation Agreement by and between Rite Aid Corporation and Darren Karst, dated as of March 12, 2019	Exhibit 10.29 to Form 10-Q, filed on July 11, 2019
10.30	Separation Agreement by and between Rite Aid Corporation and Kermit Crawford, dated as of March 12, 2019	Exhibit 10.30 to Form 10-Q, filed on July 11, 2019
10.31	Amendment to Employment Agreement by and between Rite Aid Corporation and Bryan Everett, dated as of March 12, 2019	Exhibit 10.31 to Form 10-Q, filed on July 11, 2019
10.32	Amendment to Employment Agreement by and between Rite Aid Corporation and Jocelyn Z. Konrad, dated as of March 12, 2019	Exhibit 10.32 to Form 10-Q, filed on July 11, 2019
10.33	Amendment to Employment Agreement by and between Rite Aid Corporation and Matthew C. Schroeder, dated as of March 12, 2019	Exhibit 10.33 to Form 10-Q, filed on July 11, 2019
10.34	Amendment to Employment Agreement by and between Rite Aid Corporation and Brian Hoover, dated as of March 12, 2019	Exhibit 10.34 to Form 10-Q, filed on July 11, 2019
10.35	Amendment to Employment Agreement by and between Rite Aid Corporation and Brian Hoover, dated as of December 5, 2017	Exhibit 10.35 to Form 10-Q, filed on July 11, 2019
10.36	Amendment to Employment Agreement by and between Rite Aid Corporation and Brian Hoover, dated as of August 10, 2016	Exhibit 10.36 to Form 10-Q, filed on July 11, 2019
10.37	Employment Agreement by and between Rite Aid Corporation and Brian Hoover, dated as of January 1, 2001	Exhibit 10.37 to Form 10-Q, filed on July 11, 2019
10.38	Eleventh Amendment to Supply Agreement by and between Rite Aid Corporation and McKesson Corporation, dated as of February 28, 2019*	Exhibit 10.38 to Form 10-Q, filed on July 11, 2019
10.39	Employment Agreement by and between Rite Aid Corporation and Heyward Donigan, dated August 8, 2019**	Exhibit 10.1 to Form 8-K, filed on August 12, 2019
10.40	Employment Inducement Award Agreement by and between Rite Aid Corporation and Heyward Donigan, dated August 12, 2019	Exhibit 10.2 to Form 8-K, filed on August 12, 2019

Table of Contents


Exhibit Numbers	Description	Incorporation By Reference To
10.41	Consulting Agreement by and between Rite Aid Corporation and Avalon Retail Consulting, Inc., through its president, John T. Standley, dated August 14, 2019	Exhibit 10.1 to Form 8-K, filed on August 16, 2019
31.1	Certification of CEO pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended	Filed herewith
31.2	Certification of CFO pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended	Filed herewith
32	Certification of CEO and CFO pursuant to 18 United States Code, Section 1350, as enacted by Section 906 of the Sarbanes-Oxley Act of 2002	Filed herewith
101.INS	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.	Filed herewith
101.SCH	XBRL Taxonomy Extension Schema Document.	Filed herewith
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.	Filed herewith
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.	Filed herewith
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.	Filed herewith
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.	Filed herewith
104	Cover Page Interactive Data File - The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.	Filed herewith

* Confidential portions of this Exhibit were redacted pursuant to Item 601(b)(10) of Regulation S-K and Rite Aid Corporation agrees to furnish supplementally to the Securities and Exchange Commission a copy of any omitted schedule and/or exhibit upon request.

** Certain schedules and exhibits to this agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K and Rite Aid Corporation agrees to furnish supplementally to the Securities and Exchange Commission a copy of any omitted schedule and/or exhibit upon request.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Date: October 3, 2019	RITE AID CORPORATION

	By:	/s/ MATTHEW C. SCHROEDER
		Matthew C. Schroeder
		Chief Financial Officer

Date: October 3, 2019	By:	/s/ BRIAN T. HOOVER
		Brian T. Hoover
		Senior Vice President and Chief Accounting Officer